WO2024047115A1 - THERAPEUTIC USE OF THE miR155 SNP rs377265631 - Google Patents
THERAPEUTIC USE OF THE miR155 SNP rs377265631 Download PDFInfo
- Publication number
- WO2024047115A1 WO2024047115A1 PCT/EP2023/073808 EP2023073808W WO2024047115A1 WO 2024047115 A1 WO2024047115 A1 WO 2024047115A1 EP 2023073808 W EP2023073808 W EP 2023073808W WO 2024047115 A1 WO2024047115 A1 WO 2024047115A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- cells
- seq
- cell
- immune cell
- Prior art date
Links
- 108091033773 MiR-155 Proteins 0.000 title abstract description 75
- 230000001225 therapeutic effect Effects 0.000 title abstract description 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 84
- 210000002865 immune cell Anatomy 0.000 claims abstract description 71
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 53
- 201000011510 cancer Diseases 0.000 claims abstract description 41
- 238000011282 treatment Methods 0.000 claims abstract description 33
- 150000007523 nucleic acids Chemical class 0.000 claims description 176
- 102000039446 nucleic acids Human genes 0.000 claims description 112
- 108020004707 nucleic acids Proteins 0.000 claims description 112
- 210000004027 cell Anatomy 0.000 claims description 100
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 65
- 108091008874 T cell receptors Proteins 0.000 claims description 27
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 27
- 230000014509 gene expression Effects 0.000 claims description 26
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 9
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 6
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 108091026890 Coding region Proteins 0.000 claims description 3
- 210000000265 leukocyte Anatomy 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 31
- 201000010099 disease Diseases 0.000 abstract description 29
- 239000002773 nucleotide Substances 0.000 abstract description 10
- 125000003729 nucleotide group Chemical group 0.000 abstract description 10
- 230000009286 beneficial effect Effects 0.000 abstract description 9
- 108091070501 miRNA Proteins 0.000 description 70
- 239000002679 microRNA Substances 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 30
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 108700011259 MicroRNAs Proteins 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 229920001184 polypeptide Polymers 0.000 description 18
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- -1 pri-miRs Proteins 0.000 description 15
- 235000000346 sugar Nutrition 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 230000004913 activation Effects 0.000 description 12
- 239000012636 effector Substances 0.000 description 12
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 11
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000011664 signaling Effects 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 8
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 150000008163 sugars Chemical class 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 7
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 102000052073 human NGFR Human genes 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 230000001177 retroviral effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 230000001960 triggered effect Effects 0.000 description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 5
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 5
- 229930024421 Adenine Natural products 0.000 description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 5
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 5
- 229960000643 adenine Drugs 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 230000005809 anti-tumor immunity Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000002489 hematologic effect Effects 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000004068 intracellular signaling Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 102100032816 Integrin alpha-6 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 230000008482 dysregulation Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000036284 oxygen consumption Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 2
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 2
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 2
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 2
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 2
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 2
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 2
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 description 2
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100025323 Integrin alpha-1 Human genes 0.000 description 2
- 102100032818 Integrin alpha-4 Human genes 0.000 description 2
- 102100022341 Integrin alpha-E Human genes 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102100027744 Semaphorin-4D Human genes 0.000 description 2
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000012707 chemical precursor Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000050 cytotoxic potential Toxicity 0.000 description 2
- 230000002074 deregulated effect Effects 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000006539 extracellular acidification Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 229930191479 oligomycin Natural products 0.000 description 2
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- SHVCSCWHWMSGTE-UHFFFAOYSA-N 6-methyluracil Chemical compound CC1=CC(=O)NC(=O)N1 SHVCSCWHWMSGTE-UHFFFAOYSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- LHCPRYRLDOSKHK-UHFFFAOYSA-N 7-deaza-8-aza-adenine Chemical compound NC1=NC=NC2=C1C=NN2 LHCPRYRLDOSKHK-UHFFFAOYSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- UIFFUZWRFRDZJC-UHFFFAOYSA-N Antimycin A1 Natural products CC1OC(=O)C(CCCCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-UHFFFAOYSA-N 0.000 description 1
- NQWZLRAORXLWDN-UHFFFAOYSA-N Antimycin-A Natural products CCCCCCC(=O)OC1C(C)OC(=O)C(NC(=O)c2ccc(NC=O)cc2O)C(C)OC(=O)C1CCCC NQWZLRAORXLWDN-UHFFFAOYSA-N 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 description 1
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 108010056102 CD100 antigen Proteins 0.000 description 1
- 108010017009 CD11b Antigen Proteins 0.000 description 1
- 102100038077 CD226 antigen Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 101710139831 CD82 antigen Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- QOSATKMQPHFEIW-UHFFFAOYSA-N COP(O)=S Chemical compound COP(O)=S QOSATKMQPHFEIW-UHFFFAOYSA-N 0.000 description 1
- 101100364669 Caenorhabditis elegans lin-18 gene Proteins 0.000 description 1
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 1
- 101100149686 Caenorhabditis elegans snr-4 gene Proteins 0.000 description 1
- BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102100030886 Complement receptor type 1 Human genes 0.000 description 1
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101100503636 Danio rerio fyna gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 101150018272 FYN gene Proteins 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 102100035716 Glycophorin-A Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 1
- 208000024659 Hemostatic disease Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241001559542 Hippocampus hippocampus Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 description 1
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 description 1
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 description 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 1
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 description 1
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 description 1
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 description 1
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 description 1
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 1
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 description 1
- 108091065981 Homo sapiens miR-155 stem-loop Proteins 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100039904 Integrin alpha-D Human genes 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 108010030465 Integrin alpha6beta1 Proteins 0.000 description 1
- 102100033016 Integrin beta-7 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000022435 Light chain deposition disease Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108091030146 MiRBase Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100226902 Mus musculus Fcrlb gene Proteins 0.000 description 1
- 101100236305 Mus musculus Ly9 gene Proteins 0.000 description 1
- 101100364671 Mus musculus Ryk gene Proteins 0.000 description 1
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000007497 Patched-2 Receptor Human genes 0.000 description 1
- 108010071083 Patched-2 Receptor Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100029216 SLAM family member 5 Human genes 0.000 description 1
- 102100029197 SLAM family member 6 Human genes 0.000 description 1
- 102100029198 SLAM family member 7 Human genes 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 description 1
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 description 1
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000005904 anticancer immunity Effects 0.000 description 1
- UIFFUZWRFRDZJC-SBOOETFBSA-N antimycin A Chemical compound C[C@H]1OC(=O)[C@H](CCCCCC)[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@H]1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-SBOOETFBSA-N 0.000 description 1
- PVEVXUMVNWSNIG-UHFFFAOYSA-N antimycin A3 Natural products CC1OC(=O)C(CCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O PVEVXUMVNWSNIG-UHFFFAOYSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 125000003843 furanosyl group Chemical group 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 230000008826 genomic mutation Effects 0.000 description 1
- 230000012178 germinal center formation Effects 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000056003 human IL15 Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical compound CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001452 natriuretic effect Effects 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 208000025402 neoplasm of esophagus Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HBCQSNAFLVXVAY-UHFFFAOYSA-N pyrimidine-2-thiol Chemical compound SC1=NC=CC=N1 HBCQSNAFLVXVAY-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003527 tetrahydropyrans Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Definitions
- MicroRNAs are small non-coding RNAs that control gene expression of a broad set of target genes based on sequence complementarity. By binding to the 3' untranslated regions (3'UTR) of target mRNAs, miRNAs regulate gene expression and potentially enable control of multiple gene targets within the same or distinct signaling pathways (Nat Rev Immunol.2016;16(5):279-294; Nat Rev Drug Discov.2010;9(10):775-789). Many miRNAs are dysregulated in cancer, cardiovascular and autoimmune diseases (FEBS J.2018;285(20) :3695-3716). Genomic mutations, deletion, or changes in the key enzymes in miRNA biogenesis may all lead to alterations in miRNA levels. (Nat Rev Cancer.
- microRNAs are involved in the normal functioning of eukaryotic cells. Dysregulation of micro RNAs may lead to disease and for many microRNAs a role in pathogenesis or disease has been reported (FEBS J.2018;285(20):3695-3716). Diseases associated with the dysregulation of miRNAs include cancer (Nature. 2012; 482(7385): 347-355), heart diseases (Heart. 2015; 101:921-928), kidney diseases (Nature Reviews Nephrology 2015; 11:23-33), diseases of the nervous system (Brain. 2011; 134(Ptl2): 3578-3589), obesity (Cells.
- miR155 has been used in numerous approaches, including the use of miR155 as a diagnostic or prognostic marker, therapeutic use of miR155 by inhibiting or blocking its activity, and therapeutic use by expressing miR155 in tissues or cells (Carcinogenesis. 2020; 41( 1) :2-7, Blood. 2018; 132(Supplement 1): 2903, Blood. 2011; 118(21): 2728, Int J Mol Sci. 2020; 21(16):5834) . The biology of miR155 is multi-facetted. miR155 is a key regulator of Treg homeostasis (Immunity. 2009; 30(1): 80-91).
- miR155 also promotes pro-inflammatory macrophages while inhibiting the polarization of anti-inflammatory macrophages (Cell Mol Immunol. 2009; 6(5) :343- 352). miR155 also enhances DC cytokine production and co-stimulatory function (Science. 2007; 316(5824): 608-611). miR155 also promotes B cell proliferation, survival, germinal center formation, plasma cell differentiation and antibody production (Immunity. 2007; 27(6): 847-859). miR155 also promotes Thl, Thl7, Tfh differentiation while inhibiting type 2 polarization (Immunity. 2010; 33(4): 607-619).
- miR155 also enhances NK cells proliferation, chemotaxis and effector functions (Blood 2013; 121(16): 3126- 3134; Pios One 2020; 15(2): e0225820.). Lastly, miR-155 promotes CD8+ T cell effector responses against viruses and tumors (2013 Apr 18;38(4):742-53; Nat Immunol. 2013 J un; 14(6) :593-602).
- W02007/127190 describes the development of a transgenic mouse model in which the mice express miR155. W02007/127190 does however not contemplate any therapeutic use of miR155.
- W02009/026576 discloses certain nucleic acids, so called external guide sequences (EGS), that may be used to target and thereby down-regulated the activity of miR-155.
- EGS external guide sequences
- W02010/135714 relates to the modulation of genes involved in adipocyte expression via compositions including miR155.
- W02011/029903 relates to the therapeutic use of miR's via enrichment of microRNAs in blood preparations of patients.
- One of the miRs is miR155.
- W02014/059248 relates to the enhancement of anti-cancer immunity through expression of miR155 in specific T cells.
- WO2016/077574 discloses inhibitors of miR-155 to increase atrial natriuric (ANP) levels for the treatment of cardiovascular diseases.
- WO2017/182580 relates to the treatment of production-related disorders with, among others, miR155.
- WO2018/177746 relates to the treatment of polycystic ovary syndrome with, among others, miR155.
- WO2019/227260 relates to mammalian virus-mediated miR expression, including miR155.
- W02020/002430 relates to the stimulation of mesenchymal stem cells with miRs, such as miR155.
- WO2020/221821 relates to the treatment of cognitive disorders with, among others, miR155.
- CN112481218 describes a pig miR-155 vector system.
- CN113337544 relates to a retroviral vector expressing a CAR and a microRNA, wherein said microRNA is, among others, miR155. None of the aforementioned references however mentions or otherwise anticipates nor suggests SNP4.
- SNPs single-nucleotide polymorphisms
- SNPs refer to variants of a gene in which a single nucleotide in the genome is substituted. SNPs have also been described for microRNAs.
- the SNP rs377265631 (SNP4) is one of many SNPs that were described for miR155. SNP4 carries an A-to-G variation compared to wildtype miR155: wildtype miR155 ACTCCTACATATTAGCATTAA (SEQ ID No. 1) rs377265631 (SNP4) ACTCCTACATGTTAGCATTAA (SEQ ID No. 2)
- rs377265631 The function or role of rs377265631 was unknown prior to the present invention. Herein it is demonstrated for the first time that overexpression of rs377265631 has a beneficial effect effect in the treatment of disease, such as cancer. This effect surprisingly surmounts the effect obtained with the corresponding with type microRNA.
- the present disclosure relates to a specific SNP of miR155 which surprisingly has been found to be useful in the treatment of various diseases, such as cancer.
- the present disclosure relates to a recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in medicine.
- said use in medicine is the use in the treatment of cancer.
- said use in the treatment of cancer is the treatment of a melanoma, NSCLC, sarcoma or a HPV-associated cancer.
- said nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 is operably linked to a promoter.
- said recombinant nucleic acid is encoded on an expression vector.
- said expression vector is a viral vector or a plasmid.
- recombinant nucleic acid is an isolated or purified nucleic acid.
- the present disclosure relates to a recombinant immune cell comprising a nucleic acid of SEQ ID No. 2 or SEQ ID No. 5.
- recombinant immune cell is a T cell.
- said T cell is a CD8-positive T cell.
- said CD8- positive T cell is a tumor infiltrating lymphocyte (TIL) or a peripheral blood lymphocyte ( PBL) isolated from a patient afflicted with cancer.
- said immune cell further comprises a nucleic acid encoding a chimeric antigen receptor or a T cell receptor.
- the nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 is located within the coding region of said chimeric antigen receptor or said T cell receptor, such as the intracellular part of the chimeric antigen receptor or the T cell receptor.
- said chimeric antigen receptor or said T cell receptor is specific for a cancer antigen.
- said immune cell is an isolated or purified immune cell. In certain embodiments, said immune cell is a human immune cell.
- the present disclosure relates to a population of cells comprising at least one of aforementioned immune cells. In certain embodiments, the present disclosure relates to a composition comprising at least one of aforementioned immune cells and a carrier therefor, preferably a pharmaceutically acceptable carrier.
- the present disclosure relates to a recombinant immune cell, a population of cells or a composition as described herein for use in medicine.
- said use in medicine is the use in the treatment of cancer.
- said cancer is a melanoma, NSCLC, sarcoma or a HPV-associated cancer.
- miR refers to the unprocessed or processed RNA transcript from a miR gene. miRs are capable of regulating the expression of genes through interacting with messenger RNA molecules (mRNA), DNA or proteins. Typically, microRNAs are composed of nucleic acid sequences of about 19-25 nucleotides (bases) and are found in mammalian cells. Mature microRNA molecules are single stranded RNA molecules processed from double stranded precursor transcripts that form local hairpin structures. The hairpin structures are typically cleaved by RNAses, such as Dicer, Argonaut, or RNAse 111, into an active 19-25 nucleotide RNA molecule.
- RNAses such as Dicer, Argonaut, or RNAse 111
- the unprocessed miR gene transcript is also called an "miR precursor", and typically comprises an RNA transcript of about 70-100 nucleotides in length. This active 19-25 nucleotide RNA molecule is also called the "processed" miR gene transcript or "mature” miRNA.
- miR can include one or more of miR-oligonucleotides, including mature miRs, pre- miRs, pri-miRs, or a miR seed sequence. In certain embodiments, the miRs may be modified to enhance delivery.
- miR miRNA
- Various sources for miRNA (miR) information is available (e.g. the Sanger Institute, miRbase, TargetSCAN, miRDB).
- microRNA as used herein incorporates both the duplex (i.e., double stranded miRs) and single stranded miRs (i.e., mature miRs) in both the 5' to 3' direction and complementary strand in the 3' to 5' direction.
- duplex i.e., double stranded miRs
- single stranded miRs i.e., mature miRs
- CTGTTAATGCTAATCGTGATAGGGGTTTTTGCCTCCAACTGACTCCTACATATTAGCATTAACAG SEQ ID No . 3
- mature miR155 has the following sequence:
- rs377265631 and "SNP4" as used herein refer to a specific SNP of miR155.
- the unprocessed precursor of SNP4 has the following sequence:
- CTGTTAATGCTAATCGTGATAGGGGTTTTTGCCTCCAACTGACTCCTACATGTTAGCATTAACAG SEQ ID No . 5
- Processed SNP4 has the following sequence:
- SNP4 sequence of SNP4 is identical to the miR155 orthologues of orangutan, gibbon and several other species; see Table 1.
- SNP single nucleotide polymorphism
- cell refers to a single cell or a plurality of cells.
- host cell refers to a cell comprising a nucleic acid and/or a vector.
- host cell refers to a cell comprising a nucleic acid and/or a vector encoding a miR, preferably SNP4.
- miR preferably SNP4.
- Preferred host cells of the present invention are eukaryotic host cells, such as immune cells.
- Particular preferred host cells are T cells, such as CD8-positive T cells.
- T cell refers to a type of lymphocyte that plays a central role in cell- mediated immunity.
- T cells also referred to as T lymphocytes, can be distinguished from other lymphocytes, such as B cells and natural killer cells, by the presence of a T-cell receptor (TCR) on the cell surface.
- TCR T-cell receptor
- T cells There are several subsets of T cells with distinct functions, including but not limited to, T helper cells, cytotoxic T cells, memory T cells, regulatory T cells and natural killer T cells.
- the T cell is an engineered T cell.
- the T cell is a CD8-positive T cell.
- the T cell is a CAR-T cell.
- CD8 or “cluster of differentiation 8" as used herein refer to a transmembrane glycoprotein (UniProt: P01732) which is present on certain T cells and which serves as a co-receptor for the T-cell receptor (TCR). Along with the TCR, the CD8 co-receptor plays a role in T cell signaling and aiding with cytotoxic T cell-antigen interactions. T cells expressing CD8 are referred to as "CD8- positive T cells”.
- CAR or "chimeric antigen receptor” as used herein refers to an artificial cell surface receptor that is designed to bind to certain proteins on cells, for example cancer cells.
- CARs are also known as chimeric T cell receptors or chimeric immunoreceptors.
- Typical CAR comprise (i) an extracellular domain that includes a moiety that binds a target antigen; (ii) a transmembrane domain; and (ill) an intracellular signaling domain that sends activating signals when the CAR is stimulated by binding of the extracellular binding moiety with a target antigen.
- CAR-T cell refers to a T cell that has been engineered to express a chimeric antigen receptor.
- T cell receptor or "TCR” as used herein refer to a complex of integral membrane proteins that participates in the activation of T cells in response to the binding of an antigen.
- the TCR is a d isu If ide-l i n ked membrane-anchored heterodimer normally consisting of the highly variable alpha and beta chains expressed as the part of a complex with the invariant CD3 (cluster of differentiation 3) chain molecules.
- polynucleotide and/or “nucleic acid sequence” and/or “nucleic acid” as used herein refer to a sequence of nucleoside or nucleotide monomers consisting of bases, sugars and intersugar (backbone) linkages.
- the term includes DNA and RNA and can be either double stranded or single stranded, and represents the sense or antisense strand.
- the term also includes modified or substituted sequences comprising non- naturally occurring monomers or portions thereof.
- the nucleic acid sequences of the present application may be deoxyribonucleic acid sequences (DNA) or ribonucleic acid sequences (RNA) and may include naturally occurring bases including adenine, guanine, cytosine, thymidine and uracil.
- the sequences may also contain modified bases. Examples of such modified bases include aza and deaza adenine, guanine, cytosine, thymidine and uracil; and xanthine and hypoxanthine.
- the nucleic acids of the present disclosure may be isolated from biological organisms, formed by laboratory methods of genetic recombination or obtained by chemical synthesis or other known protocols for creating nucleic acids.
- modified RNA or “modified DNA” as used herein refers to a nucleic acid molecule in which one or more of the components of the nucleic acid, namely sugars, bases, and phosphate moieties, are different from that which occurs in nature.
- Such molecules have at least one modified internucleoside linkage and/or at least one sugar modification and/or at least one base modification compared to a naturally occurring ribonucleotide- or deoxyribonucleotide-based oligonucleotide.
- a modified internucleoside linkage indicates the presence of a modified version of the phosphodiester which does not occur naturally in RNA and DNA.
- internucleoside linkage modifications are and include in particular, phosphoramidate, phosphorodiamidate, phosphorothioate, phosphorodithioate, H-phosphonate, methyl phosphonate and methyl phosphonothioate.
- a sugar modification indicates the presence of a modified version of the ribosyl moiety as naturally occurring in RNA and DNA (i.e. the furanosyl moiety), such as bicyclic sugars, tetrahydropyrans, morpholinos, 2'-modified sugars, 3'-modified sugars, 4'- modified sugars, 5'- modified sugars, and 4'-subsituted sugars.
- RNA nucleotide residues such as 2'-0-a Ikyl or 2'-0-(su bstituted )a Ikyl, e.g. 2'-0- methyl, 2'-0-(2-cyanoethyl), 2'-0-(2- methoxy)ethyl (2'-M0E), 2'-0-(2-thiomethyl)ethyl; 2'- 0-(haloalkoxy)methyl, e.g.
- 2'-0-(2- chloroethoxy)methyl MCEM
- 2'-0-(2,2- dichloroethoxy)methyl DCEM
- 2'-0-alkoxycarbonyl e.g. 2'- 0-[2-(methoxycarbonyl)ethyl] (MOCE), 2'-0-[2-(N-methylcarbamoyl)ethyl] (MCE), 2'-0-[2-(N,N- dimethylcarbamoyl)ethyl] (DMCE), in particular a 2'-0-methyl modification or a 2'-0-(2- methoxy)ethyl (2'-M0E).
- BNA bridged or bicylic nucleic acid
- LNA locked nucleic acid
- xylo- LNA alpha-L-LNA, beta-D-LNA
- cEt (2'-0,4'-C constrained ethyl) LNA
- cMOEt (2'-0,4'-C constrained methoxy ethyl) LNA
- ethylene-bridged nucleic acid (ENA) hexitol nucleic acid (ETNA), fluorinated HNA (F-HNA), pyranosyl- RNA (p-RNA), 3'-deoxypyranosyl-DNA (p- DNA); or other modified sugar moieties, such as morpholino (PMO), cationic morpholino (PMOPIus) or PMO-X.
- PMO morpholino
- PMOPIus cationic morpholino
- base modification refers to the modification of a naturally occurring base in RNA and/or DNA (i.e. pyrimidine or purine base).
- Base modifications include, but are not limited to, a modified version of the natural purine and pyrimidine bases (e.g. adenine, uracil, guanine, cytosine, and thymine), such as hypoxanthine, pseudouracil, pseudothymine, 2-thiopyrimidine (e.g. 2-thiouracil, 2- thiothymine), 2,6-diaminopurine, 5-substituted pyrimidine (e.g.
- oligonucleotide comprises more than one, the same or different, internucleoside linkage modification, sugar modification and/or base modification.
- ABE adenine base editor
- A-T adenosine-to-guanosine
- G-C adenosine intermediate
- recombinant nucleic acid or “engineered nucleic acid” as used herein refer to a nucleic acid or polynucleotide that is not found in a biological organism.
- recombinant nucleic acids may be formed by laboratory methods of genetic recombination (such as molecular cloning) to create sequences that would not otherwise be found in nature.
- Recombinant nucleic acids may also be created by chemical synthesis or other known protocols for creating nucleic acids. Unless otherwise indicated, the definitions and embodiments described in this and other sections are intended to be applicable to all embodiments and aspects of the present application herein described for which they are suitable as would be understood by a person skilled in the art.
- polypeptide or "protein” as used herein describes a chain of amino acids.
- a polypeptide or protein of this disclosure can be a peptide, which usually describes a chain of amino acids of from two to about 30 amino acids.
- protein as used herein also describes a chain of amino acids having more than 30 amino acids and can be a fragment or domain of a protein or a full length protein.
- protein can refer to a linear chain of amino acids or it can refer to a chain of amino acids that has been processed and folded into a functional protein. It is understood, however, that 30 is an arbitrary number with regard to distinguishing peptides and proteins and the terms can be used interchangeably for a chain of amino acids.
- the proteins of the present disclosure can be obtained by isolation and purification of the proteins from cells where they are produced naturally, by enzymatic (e.g., proteolytic) cleavage, and/or recombinantly by expression of nucleic acid encoding the proteins or fragments of this disclosure.
- the proteins and/or fragments of this disclosure can also be obtained by chemical synthesis or other known protocols for producing proteins and fragments.
- isolated polypeptide refers to a polypeptide substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.
- vector refers to a polynucleotide that can be used to deliver a nucleic acid to the inside of a cell.
- a vector is an expression vector comprising expression control sequences (for example, a promoter) operatively linked to a nucleic acid to be expressed in a cell.
- Vectors known in the art include, but are not limited to, plasmids, phages, cosmids and viruses.
- treatment refers to administering an agent, or carrying out a procedure, for the purposes of obtaining an effect.
- the effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of affecting a partial or complete cure for a disease and/or symptoms of the disease.
- the terms include treatment of a disease or disorder (e.g.
- inflammation in a mammal, particularly in a human, and includes: (a) preventing the disease or a symptom of a disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it (e.g, including diseases that may be associated with or caused by a primary disease; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., causing regression of the disease.
- the treatment or amelioration of symptoms is based on one or more objective or subjective parameters; including the results of an examination by a physician. Accordingly, the term "treating" includes the administration of the compounds or agents of the present invention to prevent, delay, alleviate, arrest or inhibit development of the symptoms or conditions associated with diseases (e.g. inflammation).
- therapeutic effect refers to the reduction, elimination, or prevention of the disease, symptoms of the disease, or side effects of the disease in the subject.
- signaling domain or "intracellular signaling domain” in the context of a CAR-T cell refers to the intracellular domain of the CAR which transduced the activation signal.
- the signaling domain may be an effector domain that can directly or indirectly promote a biological or physiological response in a cell when receiving the appropriate signal.
- An effector domain may directly promote a cellular response.
- An effector domain may also indirectly promote a cellular response by associating with one or more other proteins that promote a cellular response, such as co-stimulatory domains. Effector domains can provide for activation of at least one function of a modified cell upon binding to the cellular marker expressed by a cancer cell.
- an effector domain can include an intracellular signaling component including a T cell receptor and a co-stimulatory domain which can include the cytoplasmic sequence from co-receptor or costimulatory molecule.
- An effector domain can include receptor signaling domains, intracellular signaling components (e.g., cytoplasmic signaling sequences), co-stimulatory domains, or combinations thereof.
- Exemplary effector domains include signaling and stimulatory domains selected from: 4-1BB (CD137), CARD11, CD3y, CD35, CD3s, CD3 ⁇ , CD27, CD28, CD79A, CD79B, DAP10, FcRa, FcRp (FcsRIb), FcRy, Fyn, HVEM (LIGHTR), ICOS, LAG 3, LAT, Lek, LRP, NKG2D, NOTCH1, pToc, PTCH2, 0X40, ROR2, Ryk, SLAMF1, Slp76, TCRoc, TCRp, TRIM, Wnt, Zap70, or any combination thereof.
- 4-1BB CD137
- CARD11 CD3y
- CD35 CD3s
- CD3 ⁇ CD27, CD28, CD79A, CD79B
- DAP10 FcRa, FcRp (FcsRIb), FcRy, Fyn
- HVEM LIGHTR
- ICOS
- effector domains include signaling and co-stimulatory domains selected from: CD86, FcyRlla, DAP12, CD30, CD40, PD-1, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, CDS, ICAM-1, GITR, BAFFR, SLAMF7, NKp80 (KLRF1), CD127, CD160, CD19, CD4, CD8oc, CD8P, IL2RP, I L2Ry, IL7Roc, ITGA4, VLA1, CD49a, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CDlld, ITGAE, CD103, ITGAL, CDlla, ITGAM, CDllb, ITGAX, CDllc, ITGB1, CD29, ITGB2, CD18, ITGB7, TNFR2, TRANCE/RANKL, DNAM1 (CD22),
- polypeptide or domain of a polypeptide refers to the amino acid sequence of said polypeptide or domain of a polypeptide and indicates that the amino acid sequence is either identical to the native version of said polypeptide or domain of a polypeptide, or a variant of said polypeptide or domain of a polypeptide which is functionally indistinguishable form from the native version of said polypeptide or domain of a polypeptide.
- an immune cell refers to any cell of hematopoietic lineage involved in regulating an immune response against an antigen (e.g., an autoantigen).
- an immune cell is, e.g., a T cell, a B cell, a dendritic cell, a monocyte, a natural killer cell, a macrophage, Langerhan's cells, or Kuffer cells.
- Preferred immune cells are T cells, such as CD8-positive T cells.
- recombinant refers to molecules or cells that are prepared, generated or created by recombinant means, such as genetic engineering or molecular biological technologies. Recombinant molecules do not occur naturally in nature.
- a recombinant polypeptide or a recombinant nucleic acid refer to a polypeptide (or nucleic acid) which has been modified or which has been put into another context (e.g. by cloning it behind certain regulatory elements, such as a promoter) as compared to the respective wild type molecule.
- a recombinant immune cell such as a recombinant T cell, comprises a recombinant polypeptide and/or a recombinant nucleic acid.
- cancer as used herein it its broadest sense refers to diseases in which abnormal cells divide without control.
- hematological cancer refers to a cancer of the blood, and includes leukemia, lymphoma and myeloma among others.
- Leukemia refers to a cancer of the blood in which too many white blood cells that are ineffective in fighting infection are made, thus crowding out the other parts that make up the blood, such as platelets and red blood cells. It is understood that cases of leukemia are classified as acute or chronic.
- leukemia include, by way of non limiting examples, acute lymphocytic leukemia (ALL); acute myeloid leukemia (AML); chronic lymphocytic leukemia (CLL); chronic myelogenous leukemia (CML); Myeloproliferative disorder/neoplasm (MPDS); and myelodysplasia syndrome.
- ALL acute lymphocytic leukemia
- AML acute myeloid leukemia
- CLL chronic lymphocytic leukemia
- CML chronic myelogenous leukemia
- MPDS Myeloproliferative disorder/neoplasm
- myelodysplasia syndrome myelodysplasia syndrome.
- Lymphoma may refer to a Hodgkin's lymphoma, both indolent and aggressive non-Hodgkin's lymphoma, Burkitt's lymphoma, and follicular lymphoma (small cell and large cell), among others.
- Solid tumor refers to tumors that usually do not contain cysts or liquid areas.
- Solid tumors as used herein include sarcomas and carcinomas, such as e.g. breast tumors, ovarian tumors, gastric tumors, lung tumors, pancreatic tumors, prostate tumors, melanoma tumors, colorectal tumors, lung tumors, head and neck tumors, bladder tumors, esophageal tumors, liver tumors, thyroid tumors non-small-cell lung cancer (NSCLC) and kidney tumors.
- NSCLC non-small-cell lung cancer
- Figure 1 shows the expression levels of miR155 and seven SNPs of miR155 compared to the housekeeping gene U6.
- Figure 2 shows that SNP4 triggers STAT5 signaling significantly stronger compared to wildtype miR155 and to control miR.
- Figure 3 visualizes the down-regulation (panel A) and up-regulation (panel B) of the genes most deregulated in CD8 + T cells upon expression of miR155 or SNP4 compared to Ctrl miR.
- Figure 4 shows the effect of the expression of various miR's on the metabolic fitness in T cell. Measured were the extracellular acidification rate (ECAR; left) and the oxygen consumption rate (OCR; right). The arrows indicate when the respective compounds were added.
- ECAR extracellular acidification rate
- OCR oxygen consumption rate
- Figure 5 shows the cytotoxic potential of CAR T cells upon expression of various miR's.
- Figure 6 summarizes the functionalities induced by various miR's in T cell. Calculated was the polyfunctional strength index.
- Figure 7 shows in more detail which combination of cytokines are simultaneously produced by subpopulations of cells in Ctrl miR, miR-155 and SNP4 overexpressing CD19-specific CAR T cells.
- the color intensity shows the percentage of subpopulations in each sample.
- Figure 8 shows CAR T cell mediated anti-tumor immunity in mice, dependent on the expression of various miR's.
- the present invention is based on the surprising finding that one specific SNP of miR155, herein referred to as SNP4, is beneficial in anti-cancer therapy.
- SNP4 is able to potentiate the anti-tumor activity of other components, such as CAR-T cells. Expression of SNP4 in such cells leads to a potentiation of anti-tumor immunity.
- the present disclosure related to a recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in medicine.
- the recombinant nucleic acid may be a precursor of the mature miR SNP4, i.e. a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 5.
- the precursor miR is processed by the cell to yield the mature miR.
- the present disclosure related to a recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 5 for use in medicine.
- the present disclosure related to a recombinant nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 5 for use in medicine.
- the recombinant nucleic acid may be the mature miR SNP4, i.e. a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2.
- the present disclosure related to a recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 for use in medicine.
- the present disclosure related to a recombinant nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 2 for use in medicine.
- the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 are DNA. In other embodiments of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 are RNA. In preferred embodiments the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 are DNA. In certain embodiments of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 are modified DNA. In certain embodiments of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 are modified RNA.
- nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 additional contains regulatory sequences, preferably 5' to the nucleic acid sequence encoding SNP4.
- the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 are integrated into the genome of a host cell.
- various technologies are available that are known to the skilled person. Such technologies include Crispr-Cas9 gene editing, as well as base editing or prime editing.
- SNP4 differs from miR155 through a single nucleotide exchange from A to G, a wildtype miR155 sequence could be directly converted into SNP4 via an adenine base editor.
- nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 are integrated into an extrachromosomal vehicle or vector, such as a plasmid.
- nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 are administered to the cell as free nucleic acid molecules. In such cases the nucleic acid molecules may be administered with additional ingredients which serve to increase the uptake and/or the stability of the nucleic acids.
- nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 is operably linked to a promoter.
- the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 is encoded on an expression vector.
- said expression vector is a viral vector or a plasmid.
- said expression vector is a viral vector.
- said expression vector is a plasmid.
- the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 is an isolated or purified nucleic acid. In certain embodiments of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 is an isolated nucleic acid. In certain embodiments of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 is a purified nucleic acid.
- the present disclosure relates to a recombinant immune cell expressing SNP4.
- the polyfunctional beneficial effect of SNP4 is so directly triggered in the immune cell which is involved in the combat against cancerous tissue. Therefore, in certain embodiments, the present disclosure relates to a recombinant immune cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5. In certain embodiments, the present disclosure relates to a recombinant immune cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2. In other embodiments, the present disclosure relates to a recombinant immune cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 5.
- the present disclosure relates to a recombinant immune cell expressing a nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 2. In yet other embodiments, the present disclosure relates to a recombinant immune cell expressing a nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 5.
- the immune cell can be any cell of the hematopoietic lineage involved in regulating an immune response against an antigen.
- Certain preferred immune cells are T cells. Therefore, in certain embodiments, the present disclosure relates to a recombinant T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5. In certain embodiments, the present disclosure relates to a recombinant T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2. In other embodiments, the present disclosure relates to a recombinant T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 5.
- the present disclosure relates to a recombinant T cell expressing a nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 2. In yet other embodiments, the present disclosure relates to a recombinant T cell expressing a nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 5.
- the T cell is a T cell which is positive for the T cell marker CD8. Therefore, in certain embodiments, the present disclosure relates to a recombinant CD8-positive T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5. In certain embodiments, the present disclosure relates to a recombinant CD8-positive T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2. In other embodiments, the present disclosure relates to a recombinant CD8-positive T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 5.
- the present disclosure relates to a recombinant CD8-positive T cell expressing a nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 2. In yet other embodiments, the present disclosure relates to a CD8-positive recombinant T cell expressing a nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 5. In certain embodiments said CD8-positive T cell is a tumor infiltrating lymphocyte (TIL) or a peripheral blood lymphocyte (PBL) isolated from a patient afflicted with cancer.
- TIL tumor infiltrating lymphocyte
- PBL peripheral blood lymphocyte
- the immune cell expressing SNP4 may also express additional recombinant proteins or polypeptides.
- the immune cell expressing SNP4 may also express a CAR. Therefore, in certain preferred embodiments the present disclosure relates to a recombinant CAR-T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5.
- the present disclosure relates to a recombinant CAR-T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2.
- the present disclosure relates to a recombinant CAR-T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 5.
- the present disclosure relates to a recombinant CAR-T cell expressing a nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 2. In yet other embodiments, the present disclosure relates to a recombinant CAR-T cell expressing a nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 5.
- the immune cell expressing SNP4 may also express a T cell receptor. Therefore, in certain preferred embodiments the present disclosure relates to a recombinant T cell expressing a T cell receptor and a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5. In certain embodiments, the present disclosure relates to a recombinantT cell expressing a T cell receptor and a nucleic acid sequence of SEQ ID No. 2. In other embodiments, the present disclosure relates to a recombinant T cell expressing a T cell receptor and a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 5.
- the present disclosure relates to a recombinantT cell expressing a T cell receptor and a nucleic acid sequence of SEQ ID No. 2. In yet other embodiments, the present disclosure relates to a recombinant T cell expressing a T cell receptor and a nucleic acid sequence of SEQ ID No. 5.
- the immune cell expressing said nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 is located within the coding region of the chimeric antigen receptor or the T cell receptor, such as the intracellular part of the chimeric antigen receptor or the T cell receptor.
- said chimeric antigen receptor or said T cell receptor is specific for a cancer antigen.
- said immune cell is an isolated or purified immune cell.
- said immune cell is an isolated immune cell.
- said immune cell is a purified immune cell.
- said immune cell is a human immune cell.
- the present disclosure relates to a population of cells comprising at least one immune cell as described herein. In certain embodiments, the present disclosure relates to a composition comprising at least one immune cell as described herein and a pharmaceutical acceptable carrier.
- the present disclosure relates to the recombinant nucleic acids of the present disclosure for use in the treatment of cancer.
- the present disclosure relates to recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in the treatment of cancer.
- the present disclosure relates to the recombinant nucleic acids of the present disclosure for use in the treatment of hematological cancer.
- the present disclosure relates to recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in the treatment of hematological cancer.
- the present disclosure relates to the recombinant nucleic acids of the present disclosure for use in the treatment of solid cancer.
- the present disclosure relates to recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No.
- the present disclosure relates to recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in the treatment of melanoma. In other embodiments, the present disclosure relates to recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in the treatment of cervical cancer. In certain embodiments said cervical cancer is HPV- associated cervical cancer. In other embodiments, the present disclosure relates to recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No.
- the present disclosure relates to recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in the treatment of acute lymphocytic leukemia (ALL).
- ALL acute lymphocytic leukemia
- the present disclosure relates to recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No.
- the present disclosure relates to recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in the treatment of non-small-cell lung cancer (NSCLC).
- NSCLC non-small-cell lung cancer
- the present disclosure relates to a method of reducing the size of a tumor in a mammal, comprising administering to the mammal a recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No.5 in an amount effective to reduce the size of the tumor in the mammal.
- the present disclosure relates to a method of reducing the size of a tumor in a mammal, comprising administering to the mammal a recombinant immune cell comprising a nucleic acid of SEQ ID No. 2 or SEQ ID No. 5. in an amount effective to reduce the size of the tumor in the mammal.
- said immune cell is autologous to the mammal. In other embodiments, said immune cell is allogeneic to the mammal.
- the present disclosure relates to a method of increasing T cell mediated immunity in a subject having a disease state comprising: isolating a population of the subject's immune cells; introducing a nucleic acid molecule encoding a chimeric antigen receptor or a T cell receptor and nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 into the isolated immune cells; and reintroducing the immune cells into said subject.
- the present disclosure relates to a method of increasing CD8+ T cell mediated immunity in a subject having a disease state comprising: isolating a population of the subject's immune cells; introducing a nucleic acid molecule encoding a SNP4 transcript into the isolated immune cells; and reintroducing immune cells into said subject.
- said nucleic acid is introduced into the immune cells by transduction or transfection.
- said immune cell is autologous to the mammal.
- said immune cells are isolated from the blood of the subject.
- the present disclosure relates to a recombinant immune cell, a population of cells or a composition according to the present disclosure for use in medicine.
- said use in medicine is the use in the treatment of cancer.
- said cancer is a melanoma, NSCLC, sarcoma or a HPV-associated cancers.
- Peripheral blood mononuclear cells for T-cell enrichment were isolated from peripheral blood of healthy donors. Collection of immune cells from those donors was performed in compliance with the Helsinki Declaration after ethical approval by the local ethical committees (National Institutes of Healrh Clinical Center, reference number NCT00001846 or Regensburg University, reference number 20- 2040-101) and signed informed consent.
- T cells were enriched with EasySepTM Human Naive CD8+ T Cell Isolation Kit II following manufacturer's protocol.
- naive human CD8+ T cells were enriched with EasySepTM Human Naive CD8+ T Cell Isolation Kit II (Stemcell Technologies) following manufacturer's protocol.
- Negatively enriched naive human CD8 + cells were activated with aCD3/CD28 Dynabeads (Thermo Fisher Scientific) for two days in AIM V medium supplemented with 5% FBS (Cytiva), 100 U/ml Penicillin, 100 pg/ml Streptomycin, 2 mM Glutamax, 10 mM HEPES (Thermo Fisher Scientific), and 40 lU/ml IL-2 (Miltenyi biotec).
- activated cells were transduced with a gamma retroviral vector overexpressing either Ctrl miR, miR-155 or SNP4 and NGFR (CD271) selection marker. Following transduction, cells were cultured in 300 lU/mL IL-2 AIM V culture medium for 7 days. Transduced cells were enriched by CD271 EasySepTM Human CD271 Positive Selection Kit II (StemCell Technologies). Generation of CD19-specific CAR CD8 + T cells overexpressing miRNA
- CD19-specific CAR T cells To generate miRNA overexpressing CD19-specific CAR T cells, cells were enriched and activated as described above. Two days after activation cells were co-transduced with a gamma retroviral vector overexpressing CD19-CAR construct (J Immunother. 2009 Sep;32(7):689-702) and a gamma-retroviral vector overexpressing either Ctrl miR, miR-155 or SNP4 and NGFR selection marker. Transduced cells were cultured in AIMV complete medium supplemented with 300 lU/ml IL-2. Transduced cells were enriched with a CD271 EasySepTM Human CD271 Positive Selection Kit II (StemCell Technologies).
- NOD scid y NOD.Cg-Prkdcscid H2rgtmlWjl/SzJ mice were purchased from The Jackson Laboratory. Two million NALM6-GL were injected IV, followed 3 days later by 7.5 x 10 5 CD19- specific CAR CD8 + T cells overexpressing either Ctrl miR, miR-155 or SNP4. Recombinant human IL-15 (NCI) was injected intraperitoneally every other day (1 pg per mouse). Tumor burden was measured using the Xenogen I VIS Lumina (Caliper Life Sciences).
- mice were injected intraperitoneally with 3 mg D-luciferin (Caliper Life Sciences) and 4 minutes after injection anesthetized mice were imaged with an exposure time of 30 seconds.
- Living Image Version 4.1 software (Caliper Life Sciences) was used to analyze the bioluminescent signals for each mouse as photons/s/cm2/sr.
- NALM6-GL acute lymphoblastic leukemia cell line, stably transfected with green fluorescent protein and luciferase
- CD19-K562 chronic myeloid leukemia cells stably expressing CD19 antigen; J Immunother. 2009 Sep;32(7):689-702
- RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (Cytiva), 100 U/mL penicillin, 100 pg/mL streptomycin, 2 mM glutamax, and 1 mM sodium pyruvate (Thermo Fisher Scientific).
- BD FACSymphonyTM a BD FACSCelestaTM or a BD FACSFusionTM flow cytometer (all from Becton Dickinson, Franklin Lakes/NJ, USA).
- BD CS&T beads were used to validate machine functionality. Fluorescence spillover compensation was performed with AbCTM Total Antibody Compensation Bead Kit (Thermo Fisher Scientific) stained with corresponding antibodies.
- Flow cytometry data were analyzed using BD FlowJoTM (Version 10.6.2).
- RNA expression levels were normalized against U6, a commonly used housekeeping non-coding RNA.
- To quantify miR-155 and U6 we isolated total RNA containing small RNAs from cells with RNeasy Plus Mini Kit (Qiagen). cDNA was synthesized using miRCURY LNA RT kit (Qiagen). qPCR was was performed by miRCURY® LNA® miRNA SYBR® Green PCR Assay (Qiagen).
- results are shown in Figure 1.
- SNP4 showed the highest expression level.
- the average expression level of SNP4 is in the range of wildtype miR155, but SNP4 shows a high degree of variability in expression, in particular with respect to higher expression levels. This finding prompted us to further investigate SNP4 and its role in CD8 T cell biology and anti-tumor function.
- Ctrl miR a scrambled control miR was used (tebubio, France, Cat no. 217CmiR0001-MR04).
- the Ctrl miR has a scrambled miR sequence:
- Results are shown in Figure 2. SNP4 triggered a significantly increased phosphorylation of STAT5 compared to wildtype miR155 and compared to the control miR. This indicates that SNP4 efficiently increases T cell activation in response to cytokine stimulation.
- T cells were resuspended in base medium supplemented with 2 mM L-glutamine.
- MST test cells were resuspended in base medium supplemented with ImM Sodium Pyruvate and 25 mM glucose.
- transduced CD8 + T cells were treated with 8 mM glucose, followed by a treatment with 3.9 pM oligomycin and with 122 mM 2DG at time points indicated on the graph ( Figure 4).
- MST experiments cells were treated with 3.75 pM oligomycin, followed by a treatment with 0.35 pM FCCP and with 1.22 pM rotenone plus 1.22 pM antimycin A at time points indicated on the graph ( Figure 4).
- Measured were the extracellular acidification rate (ECAR) and oxygen consumption rate (OCR), respectively.
- Example 6 SNP4-engineered CAR T cells exhibit enhanced cytotoxic function
- CAR T cells were engineered to express miR155, SNP4 or a Ctrl miR as described above.
- Six days following activation NGFR transduced cells were enriched by CD271 EasySepTM Human CD271 Positive Selection Kit II (StemCell Technologies).
- On day 9 post activation miRNA overexpressing CAR T cells were incubated with Nalm6-GL cells in E:T ratio of 1:20 and analyzed by Incucyte Live-Cell Analysis System (Sartorius).
- Results are shown in Figure 5.
- Nalm6-GL cells co-incubated with untransduced cells continued to grow, as indicated by increasing GFP intensity.
- GFP intensity decreased in cells co-incubated with T cells transfected with the CAR constructs.
- the CD19-specific CAR T cells expressing SNP4 showed a significantly stronger cytotoxicity compared to the CD19-specific CAR T cells expressing wildtype miR155 or Ctrl miR.
- SNP4 is able to enhance the cytotoxic function of anti-cancer agents, such as T cells expressing a CAR.
- Example 7 SNP4-engineered CAR T cells exhibit enhanced polyfunctionality
- Figure 6 shows bar charts summarizing the individual functions triggered by the various constructs by way of a polyfunctional strength index that is calculated by multiplying mean fluorescence intensity of secreted cytokines with the percentage of polyfunctional cells.
- CAR T cells expressing miR155 and SNP4 triggered a strongly increased polyfunctionality compared to CAR T cells expressing Ctrl miR.
- SNP4 expressing CAR T cells exhibited the highest PSI.
- Figure 7 shows combinations of cytokines simultaneously produced by subpopulations of cells present in the three groups of CD19-specific CAR T cells. Overexpression of SNP4 resulted in the highest polyfunctionality of CD19-specific CAR T cells leading to simultaneous production of up to eight different cytokines.
- Example 8 SNP4 further enhances CD8* CAR T cell antitumor immunity
- mice were co-transduced with gamma retroviral vector overexpressing CD19 CAR and gamma retroviral vector overexpressing either Ctrl miR, miR-155 or SNP4 and NGFR selection marker.
- NGFR transduced cells were enriched with CD271 EasySepTM Human CD271 Positive Selection Kit II (StemCell Technologies) seven days following transduction. 0.75 million 99% NGFR/70% CD19- specific CD8 + CAR cells were injected i.v. three days after 2.0 million NALM6-GL leukemia cells were injected i.v., and 1 pg rhlL-15 cytokine support was administered i.p. every other day for the duration of the experiment.
- Results are shown in Figure 8. 15 days post administration all untreated mice were dead while all three CAR T cell types mediated strong anti-tumor response (as shown by decrease of tumor cells- derived bioluminescent signals). After 35 days, mice implanted with CAR T cells expressing miR155 and SNP4 showed a clear decrease in cancerous cells, wherein the decrease is particularly pronounced in the SNP4 mice. After 65 days the effect is even more pronounced and the effect on cancer cells between miR155 mice and SNP4 mice is strongly visible.
Abstract
The present invention relates to the therapeutic use of a single nucleotide polymorphism (SNP) of miR155. The SNP has a multifunctional beneficial effect on immune cells, such as T cells and can be recombinantly employed in the treatment of diseases, such as cancer.
Description
Therapeutic use of the miR155 SNP rs377265631
Statement regarding funding
Parts of this invention were made with governmental support through the National Institutes of Health. The Government has certain rights in the invention.
Background
MicroRNAs (miRNAs; miRs) are small non-coding RNAs that control gene expression of a broad set of target genes based on sequence complementarity. By binding to the 3' untranslated regions (3'UTR) of target mRNAs, miRNAs regulate gene expression and potentially enable control of multiple gene targets within the same or distinct signaling pathways (Nat Rev Immunol.2016;16(5):279-294; Nat Rev Drug Discov.2010;9(10):775-789). Many miRNAs are dysregulated in cancer, cardiovascular and autoimmune diseases (FEBS J.2018;285(20) :3695-3716). Genomic mutations, deletion, or changes in the key enzymes in miRNA biogenesis may all lead to alterations in miRNA levels. (Nat Rev Cancer. 2011;ll(12):849-864; Nat Rev Cancer.2009;9(4):293-302). microRNAs are involved in the normal functioning of eukaryotic cells. Dysregulation of micro RNAs may lead to disease and for many microRNAs a role in pathogenesis or disease has been reported (FEBS J.2018;285(20):3695-3716). Diseases associated with the dysregulation of miRNAs include cancer (Nature. 2012; 482(7385): 347-355), heart diseases (Heart. 2015; 101:921-928), kidney diseases (Nature Reviews Nephrology 2015; 11:23-33), diseases of the nervous system (Brain. 2011; 134(Ptl2): 3578-3589), obesity (Cells. 2019; 8(8) :859) hemostatic diseases (JTH. 2015; 13(2): 170-81) and others. Depending on the type of dysregulation, various therapeutic approaches are possible. For certain diseases, in particular diseases which are caused or associated with the up-regulation of a microRNA, it might be beneficial to inhibit the functioning or the expression of the microRNA (Blood. 2018; 132(Supplement 1): 2903). For other diseases, in particular diseases which are caused or associated with the down-regulation of a microRNA, it might be beneficial to recombinantly express the microRNA or to add therapeutic agents that lead to an increased expression of the microRNA (Proc Natl Acad Sci USA. 2015; 112(2):476-81, Blood. 2015; 125(22):3377-3387).
One specific microRNA is miR155. miR155 has been used in numerous approaches, including the use of miR155 as a diagnostic or prognostic marker, therapeutic use of miR155 by inhibiting or blocking its activity, and therapeutic use by expressing miR155 in tissues or cells (Carcinogenesis. 2020; 41( 1) :2-7, Blood. 2018; 132(Supplement 1): 2903, Blood. 2011; 118(21): 2728, Int J Mol Sci. 2020; 21(16):5834) . The biology of miR155 is multi-facetted. miR155 is a key regulator of Treg homeostasis (Immunity. 2009; 30(1): 80-91). miR155 also promotes pro-inflammatory macrophages while inhibiting the polarization of anti-inflammatory macrophages (Cell Mol Immunol. 2009; 6(5) :343- 352). miR155 also enhances DC cytokine production and co-stimulatory function (Science. 2007; 316(5824): 608-611). miR155 also promotes B cell proliferation, survival, germinal center formation, plasma cell differentiation and antibody production (Immunity. 2007; 27(6): 847-859). miR155 also promotes Thl, Thl7, Tfh differentiation while inhibiting type 2 polarization (Immunity. 2010; 33(4): 607-619). miR155 also enhances NK cells proliferation, chemotaxis and effector functions (Blood 2013; 121(16): 3126- 3134; Pios One 2020; 15(2): e0225820.). Lastly, miR-155 promotes CD8+ T cell effector responses against viruses and tumors (2013 Apr 18;38(4):742-53; Nat Immunol. 2013 J un; 14(6) :593-602).
W02007/127190 describes the development of a transgenic mouse model in which the mice express miR155. W02007/127190 does however not contemplate any therapeutic use of miR155. W02009/026576 discloses certain nucleic acids, so called external guide sequences (EGS), that may be used to target and thereby down-regulated the activity of miR-155. W02010/135714 relates to the modulation of genes involved in adipocyte expression via compositions including miR155. W02011/029903 relates to the therapeutic use of miR's via enrichment of microRNAs in blood preparations of patients. One of the miRs is miR155. W02014/059248 relates to the enhancement of anti-cancer immunity through expression of miR155 in specific T cells. A similar concept is disclosed in WO2014/066137. WO2016/077574 discloses inhibitors of miR-155 to increase atrial natriuric (ANP) levels for the treatment of cardiovascular diseases. WO2017/182580 relates to the treatment of production-related disorders with, among others, miR155. WO2018/177746 relates to the treatment of polycystic ovary syndrome with, among others, miR155. WO2019/227260 relates to mammalian virus-mediated miR expression, including miR155. W02020/002430 relates to the stimulation of mesenchymal stem cells with miRs, such as miR155. WO2020/221821 relates to the treatment of cognitive disorders with, among others, miR155. CN112481218 describes a pig miR-155 vector system. CN113337544 relates to a retroviral vector expressing a CAR and a microRNA, wherein said microRNA is, among others, miR155. None of the aforementioned references however mentions or otherwise anticipates nor suggests SNP4.
For many genes single-nucleotide polymorphisms (SNPs) are described. SNPs refer to variants of a gene in which a single nucleotide in the genome is substituted. SNPs have also been described for
microRNAs. The SNP rs377265631 (SNP4) is one of many SNPs that were described for miR155. SNP4 carries an A-to-G variation compared to wildtype miR155: wildtype miR155 ACTCCTACATATTAGCATTAA (SEQ ID No. 1) rs377265631 (SNP4) ACTCCTACATGTTAGCATTAA (SEQ ID No. 2)
The function or role of rs377265631 was unknown prior to the present invention. Herein it is demonstrated for the first time that overexpression of rs377265631 has a beneficial effect effect in the treatment of disease, such as cancer. This effect surprisingly surmounts the effect obtained with the corresponding with type microRNA.
Summary of the invention
The present disclosure relates to a specific SNP of miR155 which surprisingly has been found to be useful in the treatment of various diseases, such as cancer. In certain embodiments, the present disclosure relates to a recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in medicine. In certain embodiments said use in medicine is the use in the treatment of cancer. In certain embodiments, said use in the treatment of cancer is the treatment of a melanoma, NSCLC, sarcoma or a HPV-associated cancer.
In certain embodiments, said nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 is operably linked to a promoter. In certain embodiments, said recombinant nucleic acid is encoded on an expression vector. In certain embodiments, said expression vector is a viral vector or a plasmid. In certain embodiments, recombinant nucleic acid is an isolated or purified nucleic acid.
In certain embodiments, the present disclosure relates to a recombinant immune cell comprising a nucleic acid of SEQ ID No. 2 or SEQ ID No. 5. In certain embodiments, recombinant immune cell is a T cell. In certain embodiments, said T cell is a CD8-positive T cell. In certain embodiments, said CD8- positive T cell is a tumor infiltrating lymphocyte (TIL) or a peripheral blood lymphocyte ( PBL) isolated from a patient afflicted with cancer. In certain embodiments, said immune cell further comprises a nucleic acid encoding a chimeric antigen receptor or a T cell receptor.
In certain embodiments, the nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 is located within the coding region of said chimeric antigen receptor or said T cell receptor, such as the intracellular part of the chimeric antigen receptor or the T cell receptor. In certain
embodiments, said chimeric antigen receptor or said T cell receptor is specific for a cancer antigen. In certain embodiments, said immune cell is an isolated or purified immune cell. In certain embodiments, said immune cell is a human immune cell.
In certain embodiments, the present disclosure relates to a population of cells comprising at least one of aforementioned immune cells. In certain embodiments, the present disclosure relates to a composition comprising at least one of aforementioned immune cells and a carrier therefor, preferably a pharmaceutically acceptable carrier.
In certain embodiments, the present disclosure relates to a recombinant immune cell, a population of cells or a composition as described herein for use in medicine. In certain embodiments, said use in medicine is the use in the treatment of cancer. In certain embodiments, said cancer is a melanoma, NSCLC, sarcoma or a HPV-associated cancer.
Definitions
The terms "miR", "miRNA" and "microRNA" as used herein refers to the unprocessed or processed RNA transcript from a miR gene. miRs are capable of regulating the expression of genes through interacting with messenger RNA molecules (mRNA), DNA or proteins. Typically, microRNAs are composed of nucleic acid sequences of about 19-25 nucleotides (bases) and are found in mammalian cells. Mature microRNA molecules are single stranded RNA molecules processed from double stranded precursor transcripts that form local hairpin structures. The hairpin structures are typically cleaved by RNAses, such as Dicer, Argonaut, or RNAse 111, into an active 19-25 nucleotide RNA molecule. The unprocessed miR gene transcript is also called an "miR precursor", and typically comprises an RNA transcript of about 70-100 nucleotides in length. This active 19-25 nucleotide RNA molecule is also called the "processed" miR gene transcript or "mature" miRNA. It is to be understood that the term "miR" as used herein can include one or more of miR-oligonucleotides, including mature miRs, pre- miRs, pri-miRs, or a miR seed sequence. In certain embodiments, the miRs may be modified to enhance delivery. Various sources for miRNA (miR) information is available (e.g. the Sanger Institute, miRbase, TargetSCAN, miRDB). The term microRNA as used herein incorporates both the duplex (i.e., double stranded miRs) and single stranded miRs (i.e., mature miRs) in both the 5' to 3' direction and complementary strand in the 3' to 5' direction.
The terms "miR155", "miRNA155" and "microRNA155" as used herein refer to a specific microRNA with the GenelD 4O6947.The unprocessed precursor, pre-miR155, has the following sequence:
CTGTTAATGCTAATCGTGATAGGGGTTTTTGCCTCCAACTGACTCCTACATATTAGCATTAACAG (SEQ ID No . 3 )
Processed, mature miR155 has the following sequence:
ACTCCTACATATTAGCATTAA ( SEQ ID No . 1 )
Orthologues of miR155 exist in many other species:
The terms "rs377265631" and "SNP4" as used herein refer to a specific SNP of miR155. The unprocessed precursor of SNP4 has the following sequence:
CTGTTAATGCTAATCGTGATAGGGGTTTTTGCCTCCAACTGACTCCTACATGTTAGCATTAACAG (SEQ ID No . 5 )
Processed SNP4 has the following sequence:
ACTCCTACATGTTAGCATTAA ( SEQ ID No . 2 )
Of note, the sequence of SNP4 is identical to the miR155 orthologues of orangutan, gibbon and several other species; see Table 1.
The terms "SNP" and "single nucleotide polymorphism" refer to a polymorphism at a particular position in the genome of a species that varies among a population of individuals, i.e. for which two or more alternative alleles are present in a given population.
The term "cell" as used herein refers to a single cell or a plurality of cells.
The term "host cell" as used herein refers to a cell comprising a nucleic acid and/or a vector. In the context of the present disclosure, the term host cell refers to a cell comprising a nucleic acid and/or a vector encoding a miR, preferably SNP4. Such host cell will express the miR and is suitable to be used in medicine. Preferred host cells of the present invention are eukaryotic host cells, such as immune cells. Particular preferred host cells are T cells, such as CD8-positive T cells.
The term "T cell" as used herein refers to a type of lymphocyte that plays a central role in cell- mediated immunity. T cells, also referred to as T lymphocytes, can be distinguished from other lymphocytes, such as B cells and natural killer cells, by the presence of a T-cell receptor (TCR) on the cell surface. There are several subsets of T cells with distinct functions, including but not limited to, T helper cells, cytotoxic T cells, memory T cells, regulatory T cells and natural killer T cells. In certain
embodiments, the T cell is an engineered T cell. In other embodiments, the T cell is a CD8-positive T cell. In yet other embodiments, the T cell is a CAR-T cell.
The terms "CD8" or "cluster of differentiation 8" as used herein refer to a transmembrane glycoprotein (UniProt: P01732) which is present on certain T cells and which serves as a co-receptor for the T-cell receptor (TCR). Along with the TCR, the CD8 co-receptor plays a role in T cell signaling and aiding with cytotoxic T cell-antigen interactions. T cells expressing CD8 are referred to as "CD8- positive T cells".
The term "CAR" or "chimeric antigen receptor" as used herein refers to an artificial cell surface receptor that is designed to bind to certain proteins on cells, for example cancer cells. When certain CARs are expressed by a T cell, binding of the CAR extracellular binding moiety with a target antigen can activate the T cell. CARs are also known as chimeric T cell receptors or chimeric immunoreceptors. Typical CAR comprise (i) an extracellular domain that includes a moiety that binds a target antigen; (ii) a transmembrane domain; and (ill) an intracellular signaling domain that sends activating signals when the CAR is stimulated by binding of the extracellular binding moiety with a target antigen.
The term "CAR-T cell" as used herein refers to a T cell that has been engineered to express a chimeric antigen receptor.
The terms "T cell receptor" or "TCR" as used herein refer to a complex of integral membrane proteins that participates in the activation of T cells in response to the binding of an antigen. The TCR is a d isu If ide-l i n ked membrane-anchored heterodimer normally consisting of the highly variable alpha and beta chains expressed as the part of a complex with the invariant CD3 (cluster of differentiation 3) chain molecules.
The terms "polynucleotide" and/or "nucleic acid sequence" and/or "nucleic acid" as used herein refer to a sequence of nucleoside or nucleotide monomers consisting of bases, sugars and intersugar (backbone) linkages. The term includes DNA and RNA and can be either double stranded or single stranded, and represents the sense or antisense strand. The term also includes modified or substituted sequences comprising non- naturally occurring monomers or portions thereof. The nucleic acid sequences of the present application may be deoxyribonucleic acid sequences (DNA) or ribonucleic acid sequences (RNA) and may include naturally occurring bases including adenine, guanine, cytosine, thymidine and uracil. The sequences may also contain modified bases. Examples of such modified bases include aza and deaza adenine, guanine, cytosine, thymidine and uracil; and xanthine and hypoxanthine. The nucleic acids of the present disclosure may be isolated from biological organisms,
formed by laboratory methods of genetic recombination or obtained by chemical synthesis or other known protocols for creating nucleic acids.
The terms "modified RNA" or "modified DNA" as used herein refers to a nucleic acid molecule in which one or more of the components of the nucleic acid, namely sugars, bases, and phosphate moieties, are different from that which occurs in nature. Such molecules have at least one modified internucleoside linkage and/or at least one sugar modification and/or at least one base modification compared to a naturally occurring ribonucleotide- or deoxyribonucleotide-based oligonucleotide. A modified internucleoside linkage indicates the presence of a modified version of the phosphodiester which does not occur naturally in RNA and DNA. Examples of internucleoside linkage modifications are and include in particular, phosphoramidate, phosphorodiamidate, phosphorothioate, phosphorodithioate, H-phosphonate, methyl phosphonate and methyl phosphonothioate. A sugar modification indicates the presence of a modified version of the ribosyl moiety as naturally occurring in RNA and DNA (i.e. the furanosyl moiety), such as bicyclic sugars, tetrahydropyrans, morpholinos, 2'-modified sugars, 3'-modified sugars, 4'- modified sugars, 5'- modified sugars, and 4'-subsituted sugars. Examples of suitable sugar modifications are known to the skilled person in the art and include, but are not limited to, 2'- O-modified RNA nucleotide residues, such as 2'-0-a Ikyl or 2'-0-(su bstituted )a Ikyl, e.g. 2'-0- methyl, 2'-0-(2-cyanoethyl), 2'-0-(2- methoxy)ethyl (2'-M0E), 2'-0-(2-thiomethyl)ethyl; 2'- 0-(haloalkoxy)methyl, e.g. 2'-0-(2- chloroethoxy)methyl (MCEM), 2'-0-(2,2- dichloroethoxy)methyl (DCEM); 2'-0-alkoxycarbonyl, e.g. 2'- 0-[2-(methoxycarbonyl)ethyl] (MOCE), 2'-0-[2-(N-methylcarbamoyl)ethyl] (MCE), 2'-0-[2-(N,N- dimethylcarbamoyl)ethyl] (DMCE), in particular a 2'-0-methyl modification or a 2'-0-(2- methoxy)ethyl (2'-M0E). Another important modification includes bridged or bicylic nucleic acid (BNA) modified sugar moieties, such as found in e.g. locked nucleic acid (LNA), xylo- LNA, alpha-L-LNA, beta-D-LNA, cEt (2'-0,4'-C constrained ethyl) LNA, cMOEt (2'-0,4'-C constrained methoxy ethyl) LNA, ethylene-bridged nucleic acid (ENA), hexitol nucleic acid (ETNA), fluorinated HNA (F-HNA), pyranosyl- RNA (p-RNA), 3'-deoxypyranosyl-DNA (p- DNA); or other modified sugar moieties, such as morpholino (PMO), cationic morpholino (PMOPIus) or PMO-X. The term "base modification", as used herein refers to the modification of a naturally occurring base in RNA and/or DNA (i.e. pyrimidine or purine base). Base modifications include, but are not limited to, a modified version of the natural purine and pyrimidine bases (e.g. adenine, uracil, guanine, cytosine, and thymine), such as hypoxanthine, pseudouracil, pseudothymine, 2-thiopyrimidine (e.g. 2-thiouracil, 2- thiothymine), 2,6-diaminopurine, 5-substituted pyrimidine (e.g. 5-halouracil, 5-methyluracil, 5-methylcytosine) 7-deazaguanine, 7- deazaadenine, 7-aza-2,6-diaminopurine, 8-aza-7- deazaguanine, 8-aza-7-deazaadenine, or 8-aza-7- deaza-2,6-diaminopurine. It is also encompassed that said oligonucleotide comprises more than one,
the same or different, internucleoside linkage modification, sugar modification and/or base modification.
The terms "adenine base editor" or "ABE" refer to a base editor that mediates conversion of adenosine-to-guanosine (i.e. A-T to G-C) via an inosine intermediate. Numerous ABE's are known in the art including, but not limited to ABE7.10, ABE 6.3, ABE7.8 and ABE7.9.
The terms "isolated polynucleotide" or "isolated nucleic acid sequence" as used herein refer to a nucleic acid substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors, or other chemicals when chemically synthesized.
The terms "recombinant nucleic acid" or "engineered nucleic acid" as used herein refer to a nucleic acid or polynucleotide that is not found in a biological organism. For example, recombinant nucleic acids may be formed by laboratory methods of genetic recombination (such as molecular cloning) to create sequences that would not otherwise be found in nature. Recombinant nucleic acids may also be created by chemical synthesis or other known protocols for creating nucleic acids. Unless otherwise indicated, the definitions and embodiments described in this and other sections are intended to be applicable to all embodiments and aspects of the present application herein described for which they are suitable as would be understood by a person skilled in the art.
The term "polypeptide" or "protein" as used herein describes a chain of amino acids. A polypeptide or protein of this disclosure can be a peptide, which usually describes a chain of amino acids of from two to about 30 amino acids. The term protein as used herein also describes a chain of amino acids having more than 30 amino acids and can be a fragment or domain of a protein or a full length protein. Furthermore, as used herein, the term protein can refer to a linear chain of amino acids or it can refer to a chain of amino acids that has been processed and folded into a functional protein. It is understood, however, that 30 is an arbitrary number with regard to distinguishing peptides and proteins and the terms can be used interchangeably for a chain of amino acids. The proteins of the present disclosure can be obtained by isolation and purification of the proteins from cells where they are produced naturally, by enzymatic (e.g., proteolytic) cleavage, and/or recombinantly by expression of nucleic acid encoding the proteins or fragments of this disclosure. The proteins and/or fragments of this disclosure can also be obtained by chemical synthesis or other known protocols for producing proteins and fragments.
The term "isolated polypeptide" refers to a polypeptide substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.
The term "vector" as used herein refers to a polynucleotide that can be used to deliver a nucleic acid to the inside of a cell. In one embodiment, a vector is an expression vector comprising expression control sequences (for example, a promoter) operatively linked to a nucleic acid to be expressed in a cell. Vectors known in the art include, but are not limited to, plasmids, phages, cosmids and viruses.
The terms "recipient", "individual", "subject", "host", and "patient", are used interchangeably herein and refer to any mammalian subject for whom diagnosis, treatment, or therapy is desired, particularly humans.
As used herein, the terms "treatment," "treating," and the like, in some embodiments, refer to administering an agent, or carrying out a procedure, for the purposes of obtaining an effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of affecting a partial or complete cure for a disease and/or symptoms of the disease. The terms include treatment of a disease or disorder (e.g. inflammation) in a mammal, particularly in a human, and includes: (a) preventing the disease or a symptom of a disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it (e.g, including diseases that may be associated with or caused by a primary disease; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., causing regression of the disease. The treatment or amelioration of symptoms is based on one or more objective or subjective parameters; including the results of an examination by a physician. Accordingly, the term "treating" includes the administration of the compounds or agents of the present invention to prevent, delay, alleviate, arrest or inhibit development of the symptoms or conditions associated with diseases (e.g. inflammation).
The term "therapeutic effect" refers to the reduction, elimination, or prevention of the disease, symptoms of the disease, or side effects of the disease in the subject.
The terms "signaling domain" or "intracellular signaling domain" in the context of a CAR-T cell refers to the intracellular domain of the CAR which transduced the activation signal. The signaling domain may be an effector domain that can directly or indirectly promote a biological or physiological response in a cell when receiving the appropriate signal. An effector domain may directly promote a cellular response. An effector domain may also indirectly promote a cellular response by associating with one or more other proteins that promote a cellular response, such as co-stimulatory domains. Effector domains can provide for activation of at least one function of a modified cell upon binding to the cellular marker expressed by a cancer cell. Activation of the modified cell can include one or more of differentiation, proliferation and/or activation or other effector functions. In particular embodiments, an effector domain can include an intracellular signaling component including a T cell receptor and a
co-stimulatory domain which can include the cytoplasmic sequence from co-receptor or costimulatory molecule. An effector domain can include receptor signaling domains, intracellular signaling components (e.g., cytoplasmic signaling sequences), co-stimulatory domains, or combinations thereof. Exemplary effector domains include signaling and stimulatory domains selected from: 4-1BB (CD137), CARD11, CD3y, CD35, CD3s, CD3^, CD27, CD28, CD79A, CD79B, DAP10, FcRa, FcRp (FcsRIb), FcRy, Fyn, HVEM (LIGHTR), ICOS, LAG 3, LAT, Lek, LRP, NKG2D, NOTCH1, pToc, PTCH2, 0X40, ROR2, Ryk, SLAMF1, Slp76, TCRoc, TCRp, TRIM, Wnt, Zap70, or any combination thereof. Exemplary effector domains include signaling and co-stimulatory domains selected from: CD86, FcyRlla, DAP12, CD30, CD40, PD-1, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, CDS, ICAM-1, GITR, BAFFR, SLAMF7, NKp80 (KLRF1), CD127, CD160, CD19, CD4, CD8oc, CD8P, IL2RP, I L2Ry, IL7Roc, ITGA4, VLA1, CD49a, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CDlld, ITGAE, CD103, ITGAL, CDlla, ITGAM, CDllb, ITGAX, CDllc, ITGB1, CD29, ITGB2, CD18, ITGB7, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB- A, LylOS), SLAM (CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, GADS, PAG/Cbp, NKp44, NKp30, or NKp46.
The terms "is", "are", "is derived from" and "are derived from" in the context of a polypeptide or domain of a polypeptide refers to the amino acid sequence of said polypeptide or domain of a polypeptide and indicates that the amino acid sequence is either identical to the native version of said polypeptide or domain of a polypeptide, or a variant of said polypeptide or domain of a polypeptide which is functionally indistinguishable form from the native version of said polypeptide or domain of a polypeptide.
The terms "immune cell" as used herein refers to any cell of hematopoietic lineage involved in regulating an immune response against an antigen (e.g., an autoantigen). In various embodiments, an immune cell is, e.g., a T cell, a B cell, a dendritic cell, a monocyte, a natural killer cell, a macrophage, Langerhan's cells, or Kuffer cells. Preferred immune cells are T cells, such as CD8-positive T cells.
The terms "recombinant" as used herein refers to molecules or cells that are prepared, generated or created by recombinant means, such as genetic engineering or molecular biological technologies. Recombinant molecules do not occur naturally in nature. For example, a recombinant polypeptide or a recombinant nucleic acid refer to a polypeptide (or nucleic acid) which has been modified or which has been put into another context (e.g. by cloning it behind certain regulatory elements, such as a promoter) as compared to the respective wild type molecule. A recombinant immune cell, such as a recombinant T cell, comprises a recombinant polypeptide and/or a recombinant nucleic acid.
The term "cancer" as used herein it its broadest sense refers to diseases in which abnormal cells divide without control.
The term "hematological cancer" as used herein refers to a cancer of the blood, and includes leukemia, lymphoma and myeloma among others. "Leukemia" refers to a cancer of the blood in which too many white blood cells that are ineffective in fighting infection are made, thus crowding out the other parts that make up the blood, such as platelets and red blood cells. It is understood that cases of leukemia are classified as acute or chronic. Certain forms of leukemia include, by way of non limiting examples, acute lymphocytic leukemia (ALL); acute myeloid leukemia (AML); chronic lymphocytic leukemia (CLL); chronic myelogenous leukemia (CML); Myeloproliferative disorder/neoplasm (MPDS); and myelodysplasia syndrome. "Lymphoma" may refer to a Hodgkin's lymphoma, both indolent and aggressive non-Hodgkin's lymphoma, Burkitt's lymphoma, and follicular lymphoma (small cell and large cell), among others. Myeloma may refer to multiple myeloma (MM), giant cell myeloma, heavychain myeloma, and light chain or Bence-Jones myeloma.
The term "solid tumor" or "solid cancer" as used herein refers to tumors that usually do not contain cysts or liquid areas. Solid tumors as used herein include sarcomas and carcinomas, such as e.g. breast tumors, ovarian tumors, gastric tumors, lung tumors, pancreatic tumors, prostate tumors, melanoma tumors, colorectal tumors, lung tumors, head and neck tumors, bladder tumors, esophageal tumors, liver tumors, thyroid tumors non-small-cell lung cancer (NSCLC) and kidney tumors.
Figure legends
Figure 1 shows the expression levels of miR155 and seven SNPs of miR155 compared to the housekeeping gene U6.
Figure 2 shows that SNP4 triggers STAT5 signaling significantly stronger compared to wildtype miR155 and to control miR.
Figure 3 visualizes the down-regulation (panel A) and up-regulation (panel B) of the genes most deregulated in CD8+ T cells upon expression of miR155 or SNP4 compared to Ctrl miR.
Figure 4 shows the effect of the expression of various miR's on the metabolic fitness in T cell. Measured were the extracellular acidification rate (ECAR; left) and the oxygen consumption rate (OCR; right). The arrows indicate when the respective compounds were added.
Figure 5 shows the cytotoxic potential of CAR T cells upon expression of various miR's.
Figure 6 summarizes the functionalities induced by various miR's in T cell. Calculated was the polyfunctional strength index.
Figure 7 shows in more detail which combination of cytokines are simultaneously produced by subpopulations of cells in Ctrl miR, miR-155 and SNP4 overexpressing CD19-specific CAR T cells. The color intensity shows the percentage of subpopulations in each sample.
Figure 8 shows CAR T cell mediated anti-tumor immunity in mice, dependent on the expression of various miR's.
Embodiments of the invention
Nucleic acids encoding SNR 4 (rs377265631)
The present invention is based on the surprising finding that one specific SNP of miR155, herein referred to as SNP4, is beneficial in anti-cancer therapy. SNP4 is able to potentiate the anti-tumor activity of other components, such as CAR-T cells. Expression of SNP4 in such cells leads to a potentiation of anti-tumor immunity.
In certain embodiments, the present disclosure related to a recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in medicine. The recombinant nucleic acid may be a precursor of the mature miR SNP4, i.e. a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 5. The precursor miR is processed by the cell to yield the mature miR. Hence, in certain embodiments, the present disclosure related to a recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 5 for use in medicine. In other embodiments, the present disclosure related to a recombinant nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 5 for use in medicine. Alternatively. The recombinant nucleic acid may be the mature miR SNP4, i.e. a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2. Hence, in certain embodiments, the present disclosure related to a recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 for use in medicine. In other embodiments, the present disclosure related to a recombinant nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 2 for use in medicine.
In certain embodiments of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 are DNA. In other embodiments of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid
sequence of SEQ ID No. 2 or SEQ ID No. 5 are RNA. In preferred embodiments the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 are DNA. In certain embodiments of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 are modified DNA. In certain embodiments of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 are modified RNA.
In yet other embodiments of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 additional contains regulatory sequences, preferably 5' to the nucleic acid sequence encoding SNP4.
In certain embodiment of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 are integrated into the genome of a host cell. For integration of the nucleic acid into the genome various technologies are available that are known to the skilled person. Such technologies include Crispr-Cas9 gene editing, as well as base editing or prime editing. For example, since SNP4 differs from miR155 through a single nucleotide exchange from A to G, a wildtype miR155 sequence could be directly converted into SNP4 via an adenine base editor.
In other embodiment of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 are integrated into an extrachromosomal vehicle or vector, such as a plasmid. In yet other embodiment of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 are administered to the cell as free nucleic acid molecules. In such cases the nucleic acid molecules may be administered with additional ingredients which serve to increase the uptake and/or the stability of the nucleic acids.
In certain embodiments of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 is operably linked to a promoter.
In certain embodiments of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 is encoded on an expression vector. In certain embodiments said expression vector is a viral vector or a plasmid. In certain embodiments said expression vector is a viral vector. In certain embodiments said expression vector is a plasmid.
In certain embodiments of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 is an isolated or purified nucleic acid. In certain embodiments of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 is an isolated nucleic acid. In certain
embodiments of the present disclosure, the nucleic acid molecules comprising or consisting of the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 is a purified nucleic acid.
Immune cells expressing SNP4
In certain embodiments, the present disclosure relates to a recombinant immune cell expressing SNP4. The polyfunctional beneficial effect of SNP4 is so directly triggered in the immune cell which is involved in the combat against cancerous tissue. Therefore, in certain embodiments, the present disclosure relates to a recombinant immune cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5. In certain embodiments, the present disclosure relates to a recombinant immune cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2. In other embodiments, the present disclosure relates to a recombinant immune cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 5. In yet other embodiments, the present disclosure relates to a recombinant immune cell expressing a nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 2. In yet other embodiments, the present disclosure relates to a recombinant immune cell expressing a nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 5.
The immune cell can be any cell of the hematopoietic lineage involved in regulating an immune response against an antigen. Certain preferred immune cells are T cells. Therefore, in certain embodiments, the present disclosure relates to a recombinant T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5. In certain embodiments, the present disclosure relates to a recombinant T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2. In other embodiments, the present disclosure relates to a recombinant T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 5. In yet other embodiments, the present disclosure relates to a recombinant T cell expressing a nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 2. In yet other embodiments, the present disclosure relates to a recombinant T cell expressing a nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 5.
In certain preferred embodiments, the T cell is a T cell which is positive for the T cell marker CD8. Therefore, in certain embodiments, the present disclosure relates to a recombinant CD8-positive T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5. In certain embodiments, the present disclosure relates to a recombinant CD8-positive T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2. In other embodiments, the present
disclosure relates to a recombinant CD8-positive T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 5. In yet other embodiments, the present disclosure relates to a recombinant CD8-positive T cell expressing a nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 2. In yet other embodiments, the present disclosure relates to a CD8-positive recombinant T cell expressing a nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 5. In certain embodiments said CD8-positive T cell is a tumor infiltrating lymphocyte (TIL) or a peripheral blood lymphocyte (PBL) isolated from a patient afflicted with cancer.
The immune cell expressing SNP4 may also express additional recombinant proteins or polypeptides. For example, the immune cell expressing SNP4 may also express a CAR. Therefore, in certain preferred embodiments the present disclosure relates to a recombinant CAR-T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5. In certain embodiments, the present disclosure relates to a recombinant CAR-T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2. In other embodiments, the present disclosure relates to a recombinant CAR-T cell expressing a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 5. In yet other embodiments, the present disclosure relates to a recombinant CAR-T cell expressing a nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 2. In yet other embodiments, the present disclosure relates to a recombinant CAR-T cell expressing a nucleic acid consisting of the nucleic acid sequence of SEQ ID No. 5.
In other embodiments, the immune cell expressing SNP4 may also express a T cell receptor. Therefore, in certain preferred embodiments the present disclosure relates to a recombinant T cell expressing a T cell receptor and a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5. In certain embodiments, the present disclosure relates to a recombinantT cell expressing a T cell receptor and a nucleic acid sequence of SEQ ID No. 2. In other embodiments, the present disclosure relates to a recombinant T cell expressing a T cell receptor and a nucleic acid comprising the nucleic acid sequence of SEQ ID No. 5. In yet other embodiments, the present disclosure relates to a recombinantT cell expressing a T cell receptor and a nucleic acid sequence of SEQ ID No. 2. In yet other embodiments, the present disclosure relates to a recombinant T cell expressing a T cell receptor and a nucleic acid sequence of SEQ ID No. 5.
In certain embodiments, the immune cell expressing said nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 is located within the coding region of the chimeric antigen receptor or the T cell receptor, such as the intracellular part of the chimeric antigen receptor or the T cell receptor. In certain embodiments, said chimeric antigen receptor or said T cell receptor is specific for a cancer antigen.
In certain embodiments of the present disclosure, said immune cell is an isolated or purified immune cell. In certain embodiments, said immune cell is an isolated immune cell. In certain embodiments, said immune cell is a purified immune cell. In certain embodiments, said immune cell is a human immune cell.
In certain embodiments, the present disclosure relates to a population of cells comprising at least one immune cell as described herein. In certain embodiments, the present disclosure relates to a composition comprising at least one immune cell as described herein and a pharmaceutical acceptable carrier.
Therapeutic use
Expression of SNP4 elicits a beneficial effect in anti-cancer therapy. Expression of SNP4 also leads to the potentiation of the anti-tumor activity of other components, such as CAR-T cells. Therefore, in certain embodiments, the present disclosure relates to the recombinant nucleic acids of the present disclosure for use in the treatment of cancer. In other embodiments, the present disclosure relates to recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in the treatment of cancer.
Various types of cancer may be treated with the inventive concept disclosed herein, such as hematological cancer or solid cancer. Therefore, in certain embodiments, the present disclosure relates to the recombinant nucleic acids of the present disclosure for use in the treatment of hematological cancer. In other embodiments, the present disclosure relates to recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in the treatment of hematological cancer. In other embodiments, the present disclosure relates to the recombinant nucleic acids of the present disclosure for use in the treatment of solid cancer. In other embodiments, the present disclosure relates to recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in the treatment of solid cancer. In other embodiments, the present disclosure relates to recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in the treatment of melanoma. In other embodiments, the present disclosure relates to recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in the treatment of cervical cancer. In certain embodiments said cervical cancer is HPV- associated cervical cancer. In other embodiments, the present disclosure relates to recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in the treatment of a HPV-associated cancer. In other embodiments, the present disclosure relates to
recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in the treatment of acute lymphocytic leukemia (ALL). In other embodiments, the present disclosure relates to recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No.
5 for use in the treatment of sarcoma. In other embodiments, the present disclosure relates to recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 for use in the treatment of non-small-cell lung cancer (NSCLC).
In certain embodiments, the present disclosure relates to a method of reducing the size of a tumor in a mammal, comprising administering to the mammal a recombinant nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No.5 in an amount effective to reduce the size of the tumor in the mammal.
In certain embodiments, the present disclosure relates to a method of reducing the size of a tumor in a mammal, comprising administering to the mammal a recombinant immune cell comprising a nucleic acid of SEQ ID No. 2 or SEQ ID No. 5. in an amount effective to reduce the size of the tumor in the mammal. In certain embodiments, said immune cell is autologous to the mammal. In other embodiments, said immune cell is allogeneic to the mammal.
In certain embodiments, the present disclosure relates to a method of increasing T cell mediated immunity in a subject having a disease state comprising: isolating a population of the subject's immune cells; introducing a nucleic acid molecule encoding a chimeric antigen receptor or a T cell receptor and nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 into the isolated immune cells; and reintroducing the immune cells into said subject.
In certain embodiments, the present disclosure relates to a method of increasing CD8+ T cell mediated immunity in a subject having a disease state comprising: isolating a population of the subject's immune cells; introducing a nucleic acid molecule encoding a SNP4 transcript into the isolated immune cells; and reintroducing immune cells into said subject. In certain embodiments, said nucleic acid is introduced into the immune cells by transduction or transfection. In certain embodiments, said immune cell is autologous to the mammal. In certain embodiments, said immune cells are isolated from the blood of the subject.
In certain embodiments, the present disclosure relates to a recombinant immune cell, a population of cells or a composition according to the present disclosure for use in medicine. In certain embodiments, said use in medicine is the use in the treatment of cancer. In certain embodiments, said cancer is a melanoma, NSCLC, sarcoma or a HPV-associated cancers.
Examples
Example 1: Materials and methods
Ethics statement
Peripheral blood mononuclear cells for T-cell enrichment were isolated from peripheral blood of healthy donors. Collection of immune cells from those donors was performed in compliance with the Helsinki Declaration after ethical approval by the local ethical committees (National Institutes of Healrh Clinical Center, reference number NCT00001846 or Regensburg University, reference number 20- 2040-101) and signed informed consent.
Peripheral blood mononuclear cell isolation and pre-enrichment of blood lymphocytes
To isolate T cells from human blood, leukocyte reduction chambers were used. Blood was first diluted with PBS and the resulting blood and PBS mixture was split into four fractions and underlaid with an equal amount of Ficoll-Paque™ Plus (Cytiva, Sweden) Samples were centrifuged at 700 x g for 20 minutes at RT, with acceleration set to nine and brake to zero. The PBMC layer was isolated and washed twice with PBS by centrifugation at 300 x g for 10 minutes. Naive CD8 T cells were enriched with EasySep™ Human Naive CD8+ T Cell Isolation Kit II following manufacturer's protocol.
Generation of CD8+T cells overexpressing miRNA
To generate miRNA overexpressing T cells, naive human CD8+ T cells were enriched with EasySep™ Human Naive CD8+ T Cell Isolation Kit II (Stemcell Technologies) following manufacturer's protocol. Negatively enriched naive human CD8+ cells were activated with aCD3/CD28 Dynabeads (Thermo Fisher Scientific) for two days in AIM V medium supplemented with 5% FBS (Cytiva), 100 U/ml Penicillin, 100 pg/ml Streptomycin, 2 mM Glutamax, 10 mM HEPES (Thermo Fisher Scientific), and 40 lU/ml IL-2 (Miltenyi biotec). To generate miRNA overexpressing cells activated cells were transduced with a gamma retroviral vector overexpressing either Ctrl miR, miR-155 or SNP4 and NGFR (CD271) selection marker. Following transduction, cells were cultured in 300 lU/mL IL-2 AIM V culture medium for 7 days. Transduced cells were enriched by CD271 EasySep™ Human CD271 Positive Selection Kit II (StemCell Technologies).
Generation of CD19-specific CAR CD8+ T cells overexpressing miRNA
To generate miRNA overexpressing CD19-specific CAR T cells, cells were enriched and activated as described above. Two days after activation cells were co-transduced with a gamma retroviral vector overexpressing CD19-CAR construct (J Immunother. 2009 Sep;32(7):689-702) and a gamma-retroviral vector overexpressing either Ctrl miR, miR-155 or SNP4 and NGFR selection marker. Transduced cells were cultured in AIMV complete medium supplemented with 300 lU/ml IL-2. Transduced cells were enriched with a CD271 EasySep™ Human CD271 Positive Selection Kit II (StemCell Technologies).
Mice
Animal studies were carried out under protocols approved by the NCI Bethesda Animal Care and Use Committee. NOD scid y, NOD.Cg-Prkdcscid H2rgtmlWjl/SzJ (NSG) mice were purchased from The Jackson Laboratory. Two million NALM6-GL were injected IV, followed 3 days later by 7.5 x 105 CD19- specific CAR CD8+ T cells overexpressing either Ctrl miR, miR-155 or SNP4. Recombinant human IL-15 (NCI) was injected intraperitoneally every other day (1 pg per mouse). Tumor burden was measured using the Xenogen I VIS Lumina (Caliper Life Sciences). NSG mice were injected intraperitoneally with 3 mg D-luciferin (Caliper Life Sciences) and 4 minutes after injection anesthetized mice were imaged with an exposure time of 30 seconds. Living Image Version 4.1 software (Caliper Life Sciences) was used to analyze the bioluminescent signals for each mouse as photons/s/cm2/sr.
Cell lines
NALM6-GL (acute lymphoblastic leukemia cell line, stably transfected with green fluorescent protein and luciferase) and CD19-K562 (chronic myeloid leukemia cells stably expressing CD19 antigen; J Immunother. 2009 Sep;32(7):689-702) were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (Cytiva), 100 U/mL penicillin, 100 pg/mL streptomycin, 2 mM glutamax, and 1 mM sodium pyruvate (Thermo Fisher Scientific).
Flow cytometry
Cells were filtered with a 40 pm filter unit and acquired on a BD FACSymphony™, a BD FACSCelesta™ or a BD FACSFusion™ flow cytometer (all from Becton Dickinson, Franklin Lakes/NJ, USA). BD CS&T beads were used to validate machine functionality. Fluorescence spillover compensation was
performed with AbC™ Total Antibody Compensation Bead Kit (Thermo Fisher Scientific) stained with corresponding antibodies. Flow cytometry data were analyzed using BD FlowJo™ (Version 10.6.2).
Samples were stained either in 5 ml polystyrene tubes or 96-well plates in FACS buffer (1% FCS in PBS). LIVE/DEAD™ Fixable Dead Cell Stain (Thermo Fisher scientific) was used to discriminate dead cells. Following antibodies were used for surface staining of human CD8 T cells samples: anti-CD3 (SK7), anti-CD8 (SKI), anti-NGFR (ME20.4), anti-CD45RA (MEM-56), anti-CD45RO (UCHL1), anti-CD62L (DREG- 56), anti-CCR7 (150503), anti-CD25 (BC96), pStat5 (SRBCZX), and anti-CD19 CAR (KI P-1).
Example 2: miR155 SNP4 is overexpressed in human CD8-positive T cells
The expression of miR155 and several SNPs of miR155 after transduction of human CD8 T cells with gamma retroviral vectors expressing either Ctrl miR, miR155 or SNP4, was tested in human CD8+T cells (enriched and transduced as described in Example 1). The SNPs analyzed are shown in the following table:
Expression levels were normalized against U6, a commonly used housekeeping non-coding RNA. To quantify miR-155 and U6 we isolated total RNA containing small RNAs from cells with RNeasy Plus Mini Kit (Qiagen). cDNA was synthesized using miRCURY LNA RT kit (Qiagen). qPCR was was performed by miRCURY® LNA® miRNA SYBR® Green PCR Assay (Qiagen). We used hsa-miR-155-5p miRCURY LNA primer set to quantify miR155 and hsa -6-snRNA miRCURY LNA prmer set for U6.
Results are shown in Figure 1. Among all SNPs tested, SNP4 showed the highest expression level. The average expression level of SNP4 is in the range of wildtype miR155, but SNP4 shows a high degree of variability in expression, in particular with respect to higher expression levels. This finding prompted us to further investigate SNP4 and its role in CD8 T cell biology and anti-tumor function.
Example 3: SNP4 triggers stronger STAT5 signaling than wildtype miR155
Next, we investigated the effect of SNP4 on STAT5 signaling compared to wildtype miR155 and to a control miR. As a control miR (Ctrl miR) a scrambled control miR was used (tebubio, France, Cat no. 217CmiR0001-MR04). The Ctrl miR has a scrambled miR sequence:
GTAGGTCGACGTTTAAACGCGATCGCAGATCTGCATGTCGATAACGCAGAGACTCAACACCCTGTTTATT GATGCTGATGAATGACAGCTCGTAATTCAGTGACTGACTGGCCAGGTTCATCTGCTGTAATAACGCCCCG GACGCGGGAGTGGCCGAGGCGTTAGCAGAGAATAACAGGCTACCTGTCACTAATGACATGGCAAACCA
AAGTTGCTTCAAAGCTTGATGAATTGAAGCTTTTTTGAATTC (SEQ I D No. 12)
To measure STAT5 phosphorylation human naive CD8 T cells were transduced as described above. 7 days post-transduction, cells were starved of cytokines for 24 h and then cytokines were added back for either 20 minutes before pStat5 levels were measured by flow cytometry.
Results are shown in Figure 2. SNP4 triggered a significantly increased phosphorylation of STAT5 compared to wildtype miR155 and compared to the control miR. This indicates that SNP4 efficiently increases T cell activation in response to cytokine stimulation.
Example 4: SNP4 de-regulates miR155 target genes more robust than wildtype miR155
Next, we investigated the transcriptional changes triggered by SNP4 in comparison to miR155 and a control miR (SEQ ID No. 12). Human CD8+T cells overexpressing either Ctrl miR, miR-155 or SNP4 were generated by transduction of human naive CD8+ T cells as described above. Transduced cells were enriched on day 6. NGFR enriched cells were lysed with RLT buffer (Qiagen) on day 9 (day 7 post transduction), lysates were frozen at -80°C and kept until total RNA isolation for total RNA sequencing.
The most prominently deregulated genes were selected. The level of deregulation of these genes is visualized in Figure 3. Interestingly, the genes de-regulated by SNP4 appear to be the same as those that are de-regulated by miR155. Even more interestingly the level of de-regulation (down-regulation, as seen in panel A of Figure 3 and up-regulation, as seen in panel B of Figure 3) seem to be more pronounced for SNP4 as compared to miR155. This implies that SNP4 elicits the same transcriptional changes but to a stronger degree, further implying a potential beneficial role of SNP4 expression in cancer treatment.
Example 5: SNP4 enhance the metabolic fitness of T cells
In this experiment the metabolic fitness of T cell upon overexpression of wildtype miR155, SNP4 and a Ctrl miR was tested. Naive CD8+ T cells were activated, transduced and cultured as described above. On day 6 post activation transduced cells were enriched with CD271 EasySep™ Human CD271 Positive Selection Kit II (StemCell Technologies). On day 9 post activation metabolism of NGFR enriched cells
was studied by Agilent Seahorse XF Glycolisis Stress Test (GST) and Mito-Stress Test (MST). Base medium was prepared by supplementing serum-free DMEM medium with 143 mM NaCI, 3mg/l Phenol Red, followed by adjusting pH to 7.35. For GST experiments, T cells were resuspended in base medium supplemented with 2 mM L-glutamine. For MST test cells were resuspended in base medium supplemented with ImM Sodium Pyruvate and 25 mM glucose.
In GST experiments, transduced CD8+ T cells were treated with 8 mM glucose, followed by a treatment with 3.9 pM oligomycin and with 122 mM 2DG at time points indicated on the graph (Figure 4). In MST experiments, cells were treated with 3.75 pM oligomycin, followed by a treatment with 0.35 pM FCCP and with 1.22 pM rotenone plus 1.22 pM antimycin A at time points indicated on the graph (Figure 4). Measured were the extracellular acidification rate (ECAR) and oxygen consumption rate (OCR), respectively.
Results are shown in Figure 4. In accordance with their enhanced effector function, cells overexpressing either wt miR-155 or SNP4 were more glycolytic compared to Ctrl cells. Interestingly, cells overexpressing SNP4 had higher oxygen consumption rate compared to other two cell types, indicating their higher capacity to produce energy under condition of increased stress. In summary, these data confirm the metabolic advantage of T cells expressing SNP4.
Example 6: SNP4-engineered CAR T cells exhibit enhanced cytotoxic function
In this experiment it was tested if SNP4 is also able to enhance the cytotoxic potential of CD19-specific CAR T cells. CAR T cells were engineered to express miR155, SNP4 or a Ctrl miR as described above. Six days following activation NGFR transduced cells were enriched by CD271 EasySep™ Human CD271 Positive Selection Kit II (StemCell Technologies). On day 9 post activation miRNA overexpressing CAR T cells were incubated with Nalm6-GL cells in E:T ratio of 1:20 and analyzed by Incucyte Live-Cell Analysis System (Sartorius).
Results are shown in Figure 5. Nalm6-GL cells co-incubated with untransduced cells continued to grow, as indicated by increasing GFP intensity. GFP intensity decreased in cells co-incubated with T cells transfected with the CAR constructs. The CD19-specific CAR T cells expressing SNP4 showed a significantly stronger cytotoxicity compared to the CD19-specific CAR T cells expressing wildtype miR155 or Ctrl miR.
This experiment demonstrates that SNP4 is able to enhance the cytotoxic function of anti-cancer agents, such as T cells expressing a CAR.
Example 7: SNP4-engineered CAR T cells exhibit enhanced polyfunctionality
In this experiment, polyfunctionality of miRNA overexpressing CAR T cells were tested. Cells were transduced as described above. On day 6 post activation cells were enriched with CD271 EasySep™ Human CD271 Positive Selection Kit II (StemCell Technologies). On day 9 post activation cells were incubated with CD19-K562 target cells for 16 h. After 16 h, target cells were depleted by CD235a magnetic labeling (Miltenyi biotec) and T cells were analyzed by IsoLight technology.
Figure 6 shows bar charts summarizing the individual functions triggered by the various constructs by way of a polyfunctional strength index that is calculated by multiplying mean fluorescence intensity of secreted cytokines with the percentage of polyfunctional cells. CAR T cells expressing miR155 and SNP4 triggered a strongly increased polyfunctionality compared to CAR T cells expressing Ctrl miR. SNP4 expressing CAR T cells exhibited the highest PSI. Figure 7 shows combinations of cytokines simultaneously produced by subpopulations of cells present in the three groups of CD19-specific CAR T cells. Overexpression of SNP4 resulted in the highest polyfunctionality of CD19-specific CAR T cells leading to simultaneous production of up to eight different cytokines.
In summary, this experiment confirms the beneficial function of T cells expressing SNP4. It also demonstrates that this is mainly due to stimulatory effects which are triggered by SNP4.
Example 8: SNP4 further enhances CD8* CAR T cell antitumor immunity
In this experiment, it was tested if SNP4 is able to enhance CAR T cell antitumor immunity in mice. To that end human CD8+T cells were co-transduced with gamma retroviral vector overexpressing CD19 CAR and gamma retroviral vector overexpressing either Ctrl miR, miR-155 or SNP4 and NGFR selection marker. NGFR transduced cells were enriched with CD271 EasySep™ Human CD271 Positive Selection Kit II (StemCell Technologies) seven days following transduction. 0.75 million 99% NGFR/70% CD19- specific CD8+ CAR cells were injected i.v. three days after 2.0 million NALM6-GL leukemia cells were injected i.v., and 1 pg rhlL-15 cytokine support was administered i.p. every other day for the duration of the experiment.
Results are shown in Figure 8. 15 days post administration all untreated mice were dead while all three CAR T cell types mediated strong anti-tumor response (as shown by decrease of tumor cells-
derived bioluminescent signals). After 35 days, mice implanted with CAR T cells expressing miR155 and SNP4 showed a clear decrease in cancerous cells, wherein the decrease is particularly pronounced in the SNP4 mice. After 65 days the effect is even more pronounced and the effect on cancer cells between miR155 mice and SNP4 mice is strongly visible.
Claims
1. A recombinant immune cell expressing a nucleic acid of SEQ ID No. 2 or SEQ ID No. 5 for use in medicine.
2. The recombinant immune cell according to claim 1, wherein said nucleic acid is operably linked to a promoter.
3. The recombinant immune cell according to claim 1 or 2, wherein said recombinant nucleic acid is encoded on an expression vector, preferably a viral vector or a plasmid.
4. The recombinant immune cell according to claim3, where in said expression vectors triggers the high level expression of the nucleic acid of SEQ ID No. 2 or SEQ ID No.5.
5. The recombinant immune cell according to any one of claims 1-4, where said immune cell further comprises a nucleic acid encoding a chimeric antigen receptor or a T cell receptor.
6. The recombinant immune cell according to claims 5, wherein the nucleic acid comprising the nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 5 is located within the coding region of said chimeric antigen receptor or said T cell receptor, preferably in the intracellular part of the chimeric antigen receptor or the T cell receptor.
7. The recombinant immune cell according to claim 5 or 6, wherein said chimeric antigen receptor or said T cell receptor is specific for a cancer antigen.
8. The recombinant immune cell according to claim any one of claims 1-7, wherein said use in medicine is the use in the treatment of cancer, preferably the treatment of a melanoma, NSCLC, sarcoma or a HPV-associated cancer.
9. The recombinant immune cell according to any one of claims 1-8, wherein said recombinant immune cell is a T cell, preferably a CD8-positive T cell, and more preferably a tumor infiltrating lymphocyte (TIL) or a peripheral blood lymphocyte ( PBL) isolated from a patient afflicted with cancer.
10. The recombinant immune cell according to any one of claims 1-9, wherein said immune cell is an isolated or purified immune cell, preferably an isolated or purified human immune cell.
11. A population of cells comprising at least one recombinant immune cell of any of claims 1-10.
12. A composition comprising at least one recombinant immune cell of any of claims 1-10 or a population of cells according to claim 11, and a pharmaceutical carrier.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22193672.7 | 2022-09-02 | ||
EP22193672 | 2022-09-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024047115A1 true WO2024047115A1 (en) | 2024-03-07 |
Family
ID=83191886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/073808 WO2024047115A1 (en) | 2022-09-02 | 2023-08-30 | THERAPEUTIC USE OF THE miR155 SNP rs377265631 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024047115A1 (en) |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007127190A2 (en) | 2006-04-24 | 2007-11-08 | The Ohio State University Research Foundation | Pre-b cell proliferation and lymphoblastic leukemia/high-grade lymphoma in mir155 transgenic mice |
WO2009026576A1 (en) | 2007-08-23 | 2009-02-26 | Keren Pharmaceuticals | Targeting rna with external guide sequences |
WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
WO2011029903A1 (en) | 2009-09-10 | 2011-03-17 | Flemming Velin | Method for the preparation of micro-rna and its therapeutic application |
WO2014059248A1 (en) | 2012-10-12 | 2014-04-17 | Philadelphia Health & Education Corporation D/B/A/ Drexel | Mir-155 enhancement of cd8+ t cell immunity |
WO2014066137A1 (en) | 2012-10-22 | 2014-05-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for enhancing cancer immunotherapy |
WO2016077574A1 (en) | 2014-11-12 | 2016-05-19 | The General Hospital Corporation | INHIBITORS OF MICRORNAs miR-155, miR-103, miR-105 and miR-107 THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF |
WO2017182580A1 (en) | 2016-04-20 | 2017-10-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the diagnosis and the treatment of reproduction-related disorders and methods for contraception |
WO2018177746A1 (en) | 2017-03-31 | 2018-10-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | A gnrh antagonist for use in the treatment of a women affected with polycystic ovary syndrome |
WO2019227260A1 (en) | 2018-05-26 | 2019-12-05 | 深圳市博奥康生物科技有限公司 | Mammalian virus-mediated mirna overexpression method |
WO2020002430A1 (en) | 2018-06-26 | 2020-01-02 | Centre Hospitalier Universitaire De Montpellier | Mirnas mir-155 and mir-27b, and use thereof for stimulating mesenchymal stem cells |
WO2020221821A1 (en) | 2019-04-30 | 2020-11-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pulsative gnrh administration for treating cognitive disorders |
CN112481218A (en) | 2020-11-24 | 2021-03-12 | 河南牧业经济学院 | Cell line for knocking out pig miR-155 gene based on CRISPR/Cas9 gene editing system and construction method |
CN113337544A (en) | 2021-07-05 | 2021-09-03 | 北京中医药大学 | Retroviral vector expressing CAR and microrna and uses thereof |
-
2023
- 2023-08-30 WO PCT/EP2023/073808 patent/WO2024047115A1/en unknown
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007127190A2 (en) | 2006-04-24 | 2007-11-08 | The Ohio State University Research Foundation | Pre-b cell proliferation and lymphoblastic leukemia/high-grade lymphoma in mir155 transgenic mice |
WO2009026576A1 (en) | 2007-08-23 | 2009-02-26 | Keren Pharmaceuticals | Targeting rna with external guide sequences |
WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
WO2011029903A1 (en) | 2009-09-10 | 2011-03-17 | Flemming Velin | Method for the preparation of micro-rna and its therapeutic application |
WO2014059248A1 (en) | 2012-10-12 | 2014-04-17 | Philadelphia Health & Education Corporation D/B/A/ Drexel | Mir-155 enhancement of cd8+ t cell immunity |
US20140120136A1 (en) * | 2012-10-12 | 2014-05-01 | The Babraham Institute | Mir-155 enhancement of cd8+ t cell immunity |
WO2014066137A1 (en) | 2012-10-22 | 2014-05-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for enhancing cancer immunotherapy |
US20150275209A1 (en) * | 2012-10-22 | 2015-10-01 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Service | Compositions and methods for enhancing cancer immunotherapy |
WO2016077574A1 (en) | 2014-11-12 | 2016-05-19 | The General Hospital Corporation | INHIBITORS OF MICRORNAs miR-155, miR-103, miR-105 and miR-107 THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF |
WO2017182580A1 (en) | 2016-04-20 | 2017-10-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the diagnosis and the treatment of reproduction-related disorders and methods for contraception |
WO2018177746A1 (en) | 2017-03-31 | 2018-10-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | A gnrh antagonist for use in the treatment of a women affected with polycystic ovary syndrome |
WO2019227260A1 (en) | 2018-05-26 | 2019-12-05 | 深圳市博奥康生物科技有限公司 | Mammalian virus-mediated mirna overexpression method |
WO2020002430A1 (en) | 2018-06-26 | 2020-01-02 | Centre Hospitalier Universitaire De Montpellier | Mirnas mir-155 and mir-27b, and use thereof for stimulating mesenchymal stem cells |
WO2020221821A1 (en) | 2019-04-30 | 2020-11-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pulsative gnrh administration for treating cognitive disorders |
CN112481218A (en) | 2020-11-24 | 2021-03-12 | 河南牧业经济学院 | Cell line for knocking out pig miR-155 gene based on CRISPR/Cas9 gene editing system and construction method |
CN113337544A (en) | 2021-07-05 | 2021-09-03 | 北京中医药大学 | Retroviral vector expressing CAR and microrna and uses thereof |
Non-Patent Citations (21)
Title |
---|
BLOOD, vol. 121, no. 16, 2013, pages 3126 - 3134 |
BLOOD., vol. 125, no. 22, 2015, pages 3377 - 3387 |
CARCINOGENESIS., vol. 41, no. 1, 2020, pages 2 - 7 |
CELL MOL IMMUNOL., vol. 6, no. 5, 2009, pages 343 - 352 |
FEBS J., vol. 285, no. 20, 2018, pages 3695 - 3716 |
HEART., vol. 101, 2015, pages 921 - 928 |
IMMUNITY., vol. 27, no. 6, 2007, pages 847 - 859 |
IMMUNITY., vol. 30, no. 1, 2009, pages 80 - 91 |
IMMUNITY., vol. 33, no. 4, 2010, pages 607 - 619 |
J IMMUNOTHER., vol. 32, no. 7, September 2009 (2009-09-01), pages 689 - 702 |
JTH., vol. 13, no. 2, 2015, pages 170 - 81 |
NAT IMMUNOL., vol. 14, no. 6, June 2013 (2013-06-01), pages 593 - 602 |
NAT REV CANCER., vol. 11, no. 12, 2011, pages 849 - 864 |
NAT REV CANCER., vol. 9, no. 4, 2009, pages 293 - 302 |
NAT REV DRUG DISCOV., vol. 9, no. 10, 2010, pages 775 - 789 |
NAT REV IMMUNOL., vol. 16, no. 5, 2016, pages 279 - 294 |
NATURE REVIEWS NEPHROLOGY, vol. 11, 2015, pages 23 - 33 |
NATURE., vol. 482, no. 7385, 2012, pages 347 - 355 |
PLOS ONE, vol. 15, no. 2, 2020, pages e0225820 |
PROC NATL ACAD SCI USA., vol. 112, no. 2, 2015, pages 476 - 81 |
SCIENCE., vol. 316, no. 5824, 2007, pages 608 - 611 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210348166A1 (en) | Immunotherapy of cancer | |
He et al. | MicroRNA-155 regulates inflammatory cytokine production in tumor-associated macrophages via targeting C/EBPβ | |
AU2018270156B2 (en) | Generating mammalian T cell activation inducible synthetic promoters (syn+pro) to improve T cell therapy | |
KR20180133840A (en) | Compositions and methods for immuno-oncology | |
KR20210016431A (en) | Chimeric antigen receptor T cells for cancer treatment (CAR-T) | |
KR20200075000A (en) | CRISPR-CAS9 editing method, composition and components of TGFBR2 in T cells for immunotherapy | |
US20220202863A1 (en) | Cells with multiplexed inhibitory rna | |
EP3942025A1 (en) | Car-t cell therapies with enhanced efficacy | |
Leong et al. | Transcriptional and post-transcriptional regulation of NK cell development and function | |
CN111801348A (en) | Activating chimeric receptors and their use in natural killer cell immunotherapy | |
US20210369779A1 (en) | Compositions and methods for immunotherapy | |
US11879137B2 (en) | Treatment of type 1 diabetes and autoimmune diseases or disorders | |
JP2023134631A (en) | IL-13 RECEPTOR α2 TARGETED, ZETAKINE DIRECTED T CELL IMMUNOTHERAPY | |
WO2024047115A1 (en) | THERAPEUTIC USE OF THE miR155 SNP rs377265631 | |
JP5098033B2 (en) | siRNA, recombinant vector expressing this siRNA, NR4A2 gene expression inhibitor, IL-17 gene expression inhibitor, and CD4 positive T cell proliferation inhibitor | |
EP3974531A1 (en) | Asymmetric sirna inhibiting expression of pd-1 | |
US20240131073A1 (en) | Mir200c-epcam axis reprogramed immune cells for enhanced anti-tumor function | |
Gordino | Regulation of human γδ T cell type 1 functional differentiation by microRNAs | |
WO2023152382A1 (en) | Artificial microrna construct | |
Castoun-Puckett | MicroRNA signature of tumor infiltrated CD8+ T lymphocytes under αPD-L1 immunotherapy treatment in the context of the melanoma murine model and the effects of miR-21 on the CD8+ T cells | |
Kerr | Modulation of T Cells to Promote an Anti-Tumor Response: Activation And Inhibition Of T Cells For Efficacy In T-Cell Lymphomas And Melanoma | |
Gordino | Targeting MicroRNAs for Modlation of the Anti-Tumor Human Gamma-Delta T Cell Differentiation | |
Nair et al. | Identification and functional characterization of TGF-β inducible, immunosuppressive miRNAs in human CD8+ T cells | |
Franceschetti | The Role of microRNAs in Osteoclastogenesis | |
Proia | T cell exhaustion and microRNAs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23764301 Country of ref document: EP Kind code of ref document: A1 |